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SUMMARY 
Amyotrophic lateral sclerosis (ALS) is a human adult-onset neurodegenerative 
disease characterized by progressive weakness, muscles atrophy, spasticity and 
paralysis resulting in respiratory arrest. These symptoms are related to degeneration 
and loss of upper motor neurons in cerebral cortex and lower motor neurons in 
brainstem and spinal cord. Most of cases of ALS are sporadic (sALS), while in the 5-
10% of cases the disease is familiar (fALS) with autosomic dominant inheritance. In 
particular, in more than 15% of cases, the fALS is caused by mutations in the gene 
coding for the Cu,Zn-superoxide dismutase SOD1. Today, more than 125 different 
mutations in this gene are known, but how SOD1 caused motor neurons degeneration 
is unclear. Interestingly, most of mutants partially preserve their enzymatic activity, 
suggesting that SOD1 mutations are associated with a gain of toxic function rather 
than a loss of function. For instance, G93A mutation, that has been studied very 
intensely, leaves the enzyme activity intact. At last, while wt SOD1 secretion is 
compromise in ALS, mutant SOD1 is not secreted and accumulates in motor neurons 
within the endoplasmic reticulum and Golgi apparatus. Furthermore, after secretion, 
SOD1, independently from its dismutase activity, induces phospholipase C (PLC)/ 
protein kinase C (PKC) transductional pathway. Very interestingly, SOD1 is released 
by microglial cells and protect against 6-hydroxy-dopamine (6OHDA) toxin. 
Accordingly, wt SOD1 administration in transgenic SOD1G93A mice ameliorates motor 
symptoms of disease with an unknown mechanism.  
Thus, starting from the hypothesis that the neuroprotective effects of SOD1 
could be due to its transductional property, we studied the effects of SOD1 and 
ApoSOD, which lacks dismutase activity, in both NSC-34 motor neurons and primary 
motor neurons exposed to the cicad neurotoxin L-beta-methylaminoalanine (L-
BMAA), a model to reproduce ALS in vitro, and in NSC-34 motor neurons exposed 
to chemical hypoxia, a model of Ca2+ and ROS-dependent neurodegeneration.  We 
showed that the exogenous administration of both SOD1 and ApoSOD, but not of 
human recombinant SOD1G93A, prevented cell death induced by the exposure to 300 
µM L-BMAA for 48 hrs or to 45 min chemical hypoxia. On the other hand, MnTMPyP 
pentachloride, a SOD mimetic drug, failed to protect neurons, thus suggesting that 
SOD1 exerts neuroprotection independently from its most common enzymatic 
function. Interestingly both the pharmacological inhibition and the knocking down of 
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MEK by PD98059 and siMEK, respectively, counteracted SOD1-induced 
neuroprotection. Analogously, the well known inhibitor of PI3’K LY294002 and the 
dominant negative form of Akt prevented SOD1-induced neuroprotective effect on 
neuronal death induced by L-BMAA and chemical hypoxia. Accordingly, wt SOD1 
and ApoSOD elicited a phosphorylation of ERK1/2 and Akt in motor neurons through 
an early increase of intracellular Ca2+ concentration, thus suggesting that a Ca2+-
dependent activation of ERK1/2 and Akt is mainly involved in SOD1-induced 
neuroprotective effects. 
Finally, SOD1 prevents ER stress induced by both L-BMAA and chemical 
hypoxia, as observed by a reduction of GRP78, CHOP, caspase-12 and caspase-3 
levels in motor neurons pre-incubated with SOD1 and then exposed to toxic stimuli. 
Collectively, our data suggest that SOD1 is able to activate Ca2+/ERK1/2/Akt 
pro-survival pathway in ALS thus exerting a neuroprotective effects independently 
from its enzymatic function.  
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I.A.  Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or 
Charcot’s disease, belongs to the motor neuron disorders, that comprise a spectrum of 
syndromes with large variety in both clinical characteristics and disease course, such 
as progressive muscular atrophy, primary lateral sclerosis, spinal muscular atrophies, 
and frontotemporal dementia (1)  (Fig. 1).  
 
 
 
Figure 1. The spectrum of motor neuron disorders 
 
 
The name comes from the Greek, and was used first in 1874 by the French 
neurologist J.M. Charcot to describe a fatal neurological syndrome with progressive 
muscle weakness, spasticity, and fasciculation. This name well describes the disease: 
indeed, “amyotrophic” means muscle wasting due to loss of trophic signals and “lateral 
sclerosis” describes the hardening of the outer part of the spinal cord as it is turned 
into connective tissue, where the corticospinal axons, connecting upper and lower 
motor centers, have degenerated. Charcot also pointed out the prognosis and that there 
was, and still is, no therapy for the disease. Today, about 150 years after the first 
clinical characterization of ALS, the mechanism(s) that lead(s) to motor neuron death 
are yet unknown. 
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ALS is a human adult-onset neurodegenerative disease characterized by 
progressive weakness, muscles atrophy, spasticity and paralysis resulting in 
respiratory failure, the primary cause of death in patients, or other pulmonary 
complications, such as pneumonia (2). These symptoms are related to degeneration 
and loss of upper motor neurons in cerebral cortex and lower motor neurons in 
brainstem and spinal cord (3-5). These neurons die in a progressive manner without 
plateaus and the disease, often, starts in one limb, and then spreads to the other limbs 
and the rest of the body.  
Motor neurons arise from the motor cortex and extend from the brain stem 
throughout the spinal cord, forming the pathway to control voluntary movement. 
Upper motor neurons carry impulses to lower motor neurons and those innervate 
muscles. Motor neuron axons are amongst the most unusual cells in the body because 
of their very large size and their role as the critical link between the motor areas of the 
brain and the muscles. The loss of these motor neurons causes the muscles under their 
control to weaken and waste away, leading to paralysis (Fig. 2). 
 
 
Figure 2. The human motor neuron system 
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I.A.1.  Epidemiology  
Amyotrophic lateral sclerosis is found all over the world and in all ethnic 
groups. The incidence appears to be homogeneous in most studied population; in 
particular, ALS affects about one-to-two individuals per 100,000 per year (6-8), with 
males being affected somewhat more frequently than females (9, 10). However, in 
recent studies, this difference has been lower and a trend showing the same incidence 
in men and women is now apparent (11). Alterations in smoking habits and occupation 
and better clinical evaluation of women may explain this phenomenon (12). 
In the 90-95% of cases, ALS affects patients who have no known relative with 
the disease, and it is defined sporadic ALS (sALS); instead, in about 5–10% of cases, 
ALS patients have a first- or second-degree relative with ALS, and the disease is then 
classified as familial ALS (fALS) (13,  14). In the familial cases, the male-to-female 
ratio is 1:1 (15). Close relatives to ALS patients have an up to 10-fold elevated risk of 
developing the disease (16).  
The average age of onset for sALS is reported to be 55–65 years of age (17, 
18), but it varies considerably; the age of onset for fALS, instead, is ten years earlier 
(15). Obviously, juvenile forms exist, with onset before the age of 25 (19), often with 
a family history (20, 21). Only 5% of ALS patients are younger than 30 years old, and 
there are cases in which the disease did not develop until the patient was over 80 years 
of age (18). The incidence of ALS increases with age up to about the age of 75, and 
then starts to drop (22). The mean survival after onset is reported to be about 3 years 
(23, 24), but with large variability; for examples, recent epidemiological studies 
indicate that 10% of patients survived for more than 10 years (25). 
Moreover, a high incidence of an ALS-like syndrome has been reported on the 
island of Guam in the Western Pacific (26). This form of ALS is associated with the 
exposure to a neurotoxin, the L-β-methylamino-L-alanine (L-BMAA) (Fig. 3); indeed, 
many animal species (including mice, rats, and monkeys) fed high levels of L-BMAA 
develop motor symptoms similar to ALS (27).  
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Figure 3. L-BMAA structure 
 
 
L-β-methylamino-L-alanine is a non proteic aminoacid produced by 
cyanobacteria, a blue-green algae common to lakes, oceans, and soils around the 
world (28, 29), and found in the seeds of the fresh false sago palm, Cycad circinalis. 
The people of this region process cycad seeds into flour, but the L-BMAA 
concentration in the flour is low and should not be sufficient to cause symptoms (30). 
However, a theory of bioaccumulation through consumption of flying foxes (bats) is 
thought to result in sufficient concentrations to give toxicity (31). 
L-BMAA was detected in 29/30 samples of blue-green algae tested from a 
variety of water sources in Scotland, Northern Ireland, the Netherlands, Israel, India, 
Australia, the United States, and elsewhere (32). It was also detected in samples from 
the Baltic Sea and oceanic blooms, suggesting that significant quantities may be 
released into the world's oceans (33). However, the concentrations found were very 
low and no BMAA has been found post mortem in affected brain areas of ALS patients 
(34, 35). Additionally, it has been noted that fish and animals may be exposed to L-
BMAA from consumption of cyanobacterial blooms in sources of drinking water (28). 
The environmental risk factors of neurodegeneration in ALS were largely 
unknown until recently. Indeed, the endemic occurrence of ALS, such as in the high-
risk areas in the Pacific, could not be fully explained by genetic factors (36-38). Cycad 
nuts, mineral content of the drinking water and the soil content became suspected as 
long-term acting environmental neurotoxic risks. Attention was especially focused on 
the fruits of the local growing cycad palms (39, 40), best of all because geographical 
incidence rates for ALS are strongly correlated with concentrations of cycasin, found  
in traditional food prepared from the toxic seed of the cycad plants (41, 42). The 
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pathogenic effect of cycasin seems to be due to a decrease of neuronal DNA-repair, 
persistent up-regulation of tau mRNA expression, and enhancement of excitatory 
neurotoxicity (43). 
Other putative environmental risk factors for ALS include exposure to 
radiation, electrical shocks, welding or soldering materials, paint- or petroleum 
industry and the dairy industry. Also the chemical agents of warfare, such as sarin and 
cyclosarin, which have effects on the nervous system, seem to be risk factors 
associated with ALS. Indeed, veterans of the Gulf War (1991–1993) have presented a 
higher incidence of ALS at younger ages (44, 45) and service in general in the US 
Armed Forces was later associated with an increased risk of ALS (46). However, a 
large follow-up study was not able to replicate these findings and, instead, an increased 
risk of brain cancer was found in Gulf War veterans (47).  
Moreover, a great study about the causes of death in Italian football player, 
performed in order to verify the use of illegal substances in Italian football, was 
conducted (48). This study showed a significantly higher incidence of ALS in the 
players: 18 developed ALS and the expected number of cases was 0.7 according to 
Italian registers (49). The same elevated risk was not found neither for professional 
cyclists and basketball players (50) nor for amateur football players or people 
performing fighting sports (51). As possible causes of the increased risk, history of 
multiple micro-traumas to the brain and spinal cord (52), strenuous physical activity, 
use of performance-enhancing drugs (53), and exposure to toxins from five pesticides 
used on the fields (49) have been put forward. 
Exposure to pesticides as also been linked to ALS in agricultural workers (54). 
In addition, exposure to heavy metals and occupation have been proposed to increase 
the risk of ALS (55-58), but, when pooled, these associations are not very strong (59-
61). Dietary habits do not seem to influence the risk of ALS (62). Furthermore, reports 
of head trauma preceding ALS (63, 64) and high levels of physical activity (65, 66) 
have been inconsistent. The only widely accepted risk factor for developing ALS is 
smoking. Although inconsistently reported (67, 68), meta-analyses of pooled data 
indicate a modest increment of risk for present and past smokers (69-71). 
However, none of the exogenous risk factors for ALS has been reported 
consistently. Although malignancies were reported in 10% of patients with motor 
neuron disease in a population study (72), this association remains unexplained.  
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Long-latency viral infections are another potential etiology of ALS (73, 74).  
Enterovirus nucleic acids have been detected by reverse transcriptase-PCR 
(polymerase chain reaction) in 15/17 spinal cords of sporadic ALS patients in a French 
study, but not in more than 20 spinal cords examined in other studies (75-79). 
In conclusion, exogenous risk factors are inconsistently reported in ALS. This 
might indicate that these risk factors do not cause the pathology. Alternatively, it might 
reflect a complex interaction between several environmental factors and specific 
genetic susceptibilities. Authors of several epidemiological studies have tried to find 
exogenous risk factors to explain sALS, but the results have been inconclusive.  
 
 
I.A.2.  Clinical signs and symptoms 
Amyotrophic lateral sclerosis is a disease of the motor system. In classical 
ALS, both lower motor neurons in the spinal cord and brainstem, and upper motor 
neurons in the precentral gyrus should be affected. The neurons die in a progressive 
manner without plateau and the main feature of the disease is the rapidly progressive 
muscle weakness without sensory signs leading to limb weakness. 
ALS usually begins in the fifth and sixth decades of life, starts in one limb and, 
then spread to the other limbs and the rest of the body. The skeletal muscles suffer 
when they are left without neuronal input. 
At onset, fatigue, cramps, muscle weakness and wasting of one or more limbs 
or fasciculation of the tongue (bulbar onset) occur (80, 81). Bulbar involvement causes 
difficulties in swallowing and respiration, and is a frequent cause of death in later 
stages of disease. 
In a typical patient, the muscles that control eye movement, bowel and bladder 
function are spared. Usually, symptoms related to the loss of lower motor neurons 
appear first and then patients show symptoms related to the loss of upper motor 
neurons. Loss of lower motor neurons results in muscle weakness, painful cramps and 
muscle fasciculations followed by muscle atrophy and loss of tendon reflexes. Features 
that arise from dysfunction of the upper motor neurons are spasticity, and brisk tendon 
reflexes, like the extensor plantar responses, the Babinski sign. When loss of both 
upper and lower motor neurons occurs, spasticity or weakness may predominate before 
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the amyotrophy develops. Moreover, pathologically increased reflexes are more 
common than loss of reflexes (82). 
ALS inevitably leads to death, usually because of respiratory failure or other 
pulmonary complications, such as pneuomonia (83).  
Traditionally, ALS is considered a pure motor neuron disease, but recent 
studies show also evidence of degeneration of different parts of the central nervous 
system (CNS) at post mortem examination. Multiple systems show widespread 
degeneration after long treatment in a respirator (84-87), but patients without respirator 
care can also be affected in non motor neuron areas (88, 89), thus suggesting the idea 
that ALS is a multi-system disease, at least in the end stage.   
The majority of ALS patients have cognitive and/or behavioral impairment and 
many patients fulfill the criteria for frontotemporal dementia (FTD) (90-92). This also 
suggests that neurons different form motor neurons can be affected (93, 94).  An 
association between ALS and FTD has been suspected for a long time; indeed, there 
are subsets of patients suffering from FTD or ALS or even coincident ALS-FTD in the 
same person (FLTD). Several studies identified a locus on chromosome 9 that is linked 
to both diseases, but no mutations have yet been found. 
Collectively, these studies suggest that ALS does not affect only motor 
neurons, but different part of the CNS, especially the frontotemporal lobe.  
 
 
I.A.3.  Pathogenesis and pathological features  
I.A.3.1 Pathogenesis  
The cause of motor neuron degeneration in ALS is unknown. Sporadic ALS is 
considered a complex multi-factorial disease, caused by the interaction of largely 
unknown genetic and environmental factors (95, 96). 
The discovery that mutations in several genes cause ALS allowed different 
theories and hypothesis about ALS pathogenesis: for example, excitotoxicity and 
oxidative stress have been investigated as pathogenetic mechanisms after the finding 
that SOD1 mutations cause familial ALS. In particular, exitotoxicity, caused by 
overstimulation of glutamate receptors, is involved in several neuronal conditions, 
such as stroke, epilepsy, and neurodegenerative disease. Upon stimulation, glutamate 
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activates AMPA (amino-3-hydroxyl-5-methyl-4-isoxazole-propionate) and NMDA 
(N-methyl-D-aspartate) receptors, resulting in an increase of intracellular Ca2+ 
concentration. Motor neurons show high levels of glutamate and AMPA receptors, 
thus they are more sensitive to exitotoxicity (97). The consequent increase of 
intracellular Ca2+ concentration, finally, cause the activation of damaging enzymes and 
mitochondrial damage, resulting in an increase of ROS production. Another example 
of excitotoxicity involvement in ALS is represented by L-BMAA, a neurotoxin that 
cause ALS/Parkinsonism in Guam: the exposure to this neurotoxin, indeed, is 
associated with high levels of glutamate.   
The involvement of SOD1 in fALS also suggests a role for oxidative stress, a 
particular condition characterized by high levels of toxic oxygen-derived species, such 
as reactive oxygen species (ROS). Indeed, it was hypothesized that the loss of SOD1 
activity cause an increase of oxidative stress in motor neurons, but it was clarified that 
SOD1 does not loss its function in ALS. Actually, it is yet unclear whether oxidative 
stress is a pathogenetic mechanism or a consequence of the degenerative disease. 
However, it is considered a risk factor for ALS, because high levels of oxidative stress 
markers are found in ALS patients.  
In the pathogenesis of ALS, also mitochondrial involvement was suggested, 
because mitochondria are the most important organelle for energy production; they 
show high levels of ROS, and are involved in apoptosis. Autopsy examinations of 
muscle, liver, lymphocytes and part of the CNS, in addition, reveal structural 
alterations in mitochondria. These alternations affect calcium uptake and alteration of 
protein expression (98). However, mitochondrial affections could determine ALS in 
different ways: increased production of ROS, reduced oxidative phosphorylation, 
increased sensitivity to exitotoxicity, release of pro-apoptotic proteins, and 
interference with axonal transport (99).  
Other pathogenetic hypotheses include protein aggregation: indeed, a particular 
feature of ALS is represented by different inclusions of misfolded protein that 
accumulates in the cytosol causing motor neurons degeneration. For this cause, it is 
suggested also the involvement of endoplasmic reticulum (ER) stress in the 
pathogenesis of ALS. ER stress include all the conditions in which the accumulation 
of misfolded proteins in the endoplasmic lumen exceed the capability for folding and 
degradation.  
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Furthermore, the hypothesis that viral infections or ensuing inflammatory 
reactions underlie ALS pathogenesis is supported by the analogy of poliovirus and 
poliomyelitis, and the reported presence of enterovirus nucleid acids and reverse 
transcriptase activity in cerebrospinal fluid of ALS patients. 
Finally, genome-wide association studies have identified mutations in several 
candidate genes as risk factors for sporadic ALS and may direct future studies to 
dissect pathways in ALS pathogenesis.  
 
I.A.3.2  Macroscopic pathological signs 
ALS patients generally show atrophy and wasting of muscles, both limb 
muscles and internal muscles, such as the diaphragm. The spinal cord is 
macroscopically atrophic, especially the cervical and lumbar enlargements. The 
ventral motor roots are atrophic and discoloured compared to the dorsal sensory roots, 
which are normal. In cases of very long duration, atrophy can be seen in the precentral 
gyrus, but otherwise the brain is often normal (100). ALS and FTD are being 
recognized more and more as overlapping syndromes (101). Patients with concomitant 
ALS and FTD may also show wasting of the frontal parts of the brain (102). 
 
I.A.3.3  Histopathology 
The pathological hallmark of ALS is degeneration of the motor system with 
massive loss of ventral horn cells along the whole spinal cord. Motor neurons are also 
lost in the brainstem and in the motor cortex and both white and gray matter are 
affected. This is accompanied by astrogliosis in large areas of the brain and spinal cord, 
including the ventral horn (103). These reactive astrocytes are in close contact with 
motor neurons but are also found at longer distance from the degenerating cells (104, 
105). 
The same type of reactive astrogliosis is seen in animal models carrying mutant 
SOD1 or TDP-43 (Transactive response DNA-binding Protein 43 kDa). In particular, 
animal models with either high or low SOD1 expression, even before the onset of 
symptoms, and animal models with expression of mutant and wild type TDP-43 
develop astogliosis (106-109). 
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SOD1-positive aggregates are also found in glial cells in ALS patients with 
SOD1 mutations (110), but, recently, SOD1-containing aggregates were found in glial 
cells in all types of ALS patients, and in both sporadic and familial cases, indicating 
that there is a general SOD1-dependent glial component in ALS (111). Whether these 
astrocytic changes are a secondary reaction to degenerate neurons, or are the primary 
toxic insult or a combination of the two is not known and is currently the subject of 
intense research in the field. 
The residual motor neurons show shrinkage, and many are filled with 
lipofuscin. The degeneration is mainly restricted to the motor neuron system. The 
hallmarks of ALS, such as atrophy of the ventral horn cells and ventral roots and 
myelin pallor in the anterolateral columns, are also seen in myelin preparations of 
spinal cord segments from ALS patients. Striated muscles show denervation atrophy.  
Oculomotor nuclei, abducens nuclei, and neurons in control of the anal and urethral 
sphincters are traditionally reported to be spared, but there have been reports of 
degeneration of these neurons too. Functional defects of the urinary tract are frequently 
reported for patients carrying the SOD1D90A mutation (112).  
As in other neurodegenerative disorders, several types of inclusion pathology 
can be seen in ALS patients. These types of structures with misfolded and aggregated 
proteins strongly suggest that protein stability, misfolding, and aggregation is central 
to the disease process. SOD1 is found in some of these structures linking SOD1 
misfolding to ALS. Anyway, none of the different inclusions found in ALS patients is 
pathognomonic for ALS.  
The main inclusions and aggregates associated with ALS are listed below:  
1. Bunina bodies.  
These small, granular, eosinophilic inclusions can be found in clusters or singly 
in the cytoplasm of the ventral horn cells, but are not detected in axons (113). Bunina 
bodies stain positively for cystatin C (114) and transferrin (115). They appear as 
electron-dense granular material containing vesicular structures and filaments by 
electron microscopy (116). It is known that 65–95% of ALS cases show Bunina bodies 
at autopsy and, being extremely rare in other neurological conditions, they are 
considered nearly pathognomonic of ALS. Bunina bodies can be found in sALS and 
non-SOD1 fALS (117), but have not been regularly detected in SOD1-reletated ALS.  
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2. Ubiquitinated inclusions.  
Present in almost all ALS patients but rarely in other conditions, ubiquitinated 
inclusions in motor neurons in the spinal cord and in the brainstem are important for 
post mortem diagnosis of ALS. These inclusions are refractory to standard stains, like 
hematoxylin and eosin staining (H&E), but immunohistochemical staining of ubiquitin 
shows fibrillar inclusions in motor neuron cell bodies or dendrites. Based on their 
appearance, they are divided into more loosely formed skein-like inclusions (SLIs) or 
compact Lewy body-like hyaline inclusions (LBHIs) (107). The ubiquitinated 
inclusions in patients with SOD1 mutations stain strongly for SOD1 (118, 119) and 
aggregated SOD1 isolated from transgenic mice expressing mutant SOD1 is also 
partially ubiquitinated (120). Recently, a major constituent of the ubiquitinated 
inclusions in sALS, in some forms of fALS, and in FTD was identified as TDP-43 
(121), a DNA/RNA binding protein of largely unknown function. The molecular forms 
of TDP-43 found in the inclusions include hyperphosphorylated C-terminally 
truncated variants. Following the discovery of TDP-43-containing inclusions in ALS 
patients, RNA biology has gained much focus to understand how these aggregates are 
linked to possible disease mechanisms. In addition, a protein with similar DNA/RNA 
binding properties as TDP-43, fused in sarcoma/translated in liposarcoma (FUS/TLS), 
is mutated in a few SOD1- and TDP-43-negative fALS families. Similar ubiquitinated 
inclusions containing the FUS/TLS protein are found in these patients, further linking 
ALS to RNA metabolism (122).  
3. Hyaline conglomerate inclusions. 
These are large inclusions (10–15 μm) with a glassy appearance by H&E. They 
stain for phosphorylated and non-phosphorylated neurofilaments and for other 
cytoplasmic proteins (123). They have also been detected in other neurological patients 
and in controls (124). 
4. Basophilic inclusions. 
These large basophilic inclusions are specific for juvenile forms of ALS. They 
are not limited to the motor system and are found in other brain regions too. A recent 
study showed that these inclusions stain positively for FUS/TLS and that patients carry 
FUS/TLS mutations (125). The inclusions are TDP-43 negative.  
5. Spheroids. 
It is known that neurofilament biology is involved in ALS. Mice 
overexpressing different human neurofilament genes develop progressive motor 
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neuron degeneration resembling ALS (126, 127). Phosphorylated neurofilaments 
accumulate into large inclusions in axons of the ventral horn cells in ALS patients 
(128). These inclusions are called spheroids and are not specific to ALS but are 
probably more frequent in ALS patients than in controls. 
6. Brannstrom bodies. 
Inclusions in ALS patients without SOD1 mutations have shown 
immunoreactivity to SOD1 in some studies (129, 130), and this is a rarely reported 
phenomenon (131, 132). Due to antibodies without the capability to distinguish 
between the majority of native SOD1 and the minute amounts of misfolded SOD1 
intracellularly, small aggregated structures may be difficult to identify. By the use of 
antipeptide antibodies that only detect misfolded SOD1, small punctuate aggregates of 
SOD1 were discovered in neurons and glial cells not only in mutant SOD1-mediated 
ALS, but also in fALS and sALS patients not carrying SOD1 mutations (133), 
indicating that SOD1 has a role in ALS in general. Similar findings were presented 
shortly afterwards in another material where oxidative modifications of wild-type 
SOD1 in sALS patients caused the protein to misfold and expose elements encoded by 
exon 4 that are normally hidden in the interior, as demonstrated by binding of a 
conformation-specific antibody (134). However, these misfolded SOD1 species were 
most likely soluble.  
 
 
I.A.4.  Diagnosis and treatment 
Actually, there is no single test or biomarker assay to set the diagnosis of ALS; 
thus, the clinical signs and symptoms due to the motor neuron death and the 
progressive nature of the disease are used for diagnosis. The criteria were defined by 
the World Federation of Neurology (El Escorial criteria) (135-137) and are based on 
clinical, neurophysiological, and neuropathological examinations. Anyway, there is a 
long list of tests that should be performed to exclude all possible ALS-mimicking 
disease (138). 
Therefore, diagnosis of ALS is difficult and often takes more than one year, 
with the median time to diagnosis reported to be 14 months (139). This is a serious 
problem, since therapeutic intervention early in the disease process is often more 
efficient and early diagnosis makes enrollment in clinical trials possible. Many 
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conditions show clinical manifestations that are similar to those of ALS; thus, 
misdiagnosis has been reported to be around 10% (140, 141), with inappropriate or 
delayed therapy as a result. 
Several attempts have been made to identify a biomarker for ALS by different 
methods, such as metabolomic profiling, proteomic profiling, and different enzyme-
linked immunosorbent assays (ELISA) in different biological samples, such as blood 
plasma and cerebrospinal fluid (CSF), and different imaging techniques (142). 
Examples of proposed biomarkers are cystatin C (143) and neurofilament light chain 
(NF-L) in CSF (144); the latter has come to be used clinically to some extent.  
Another problem concerning ALS is the pharmacological therapy. Indeed, 
today, only one drug, riluzole, is available for treatment of ALS. Molecularly, riluzole 
has anti-glutamate properties, but its precise mechanism is still unclear. However, it 
reduces the synaptic glutamate levels by inhibiting gluatamate release, and it also 
blocks ionotropic glutamate NMDA (N-methyl-D-aspartate) receptors.  In laboratory 
tests, riluzole shows anti-convulsant properties (145) and thus it was approved for ALS 
therapy in the mid-1990s (146). Riluzole can prolong the life of most ALS patients by 
at least 2–3 months (147), but there are indications that its effect, when administered 
from an early point in the disease process, may be better (138). Subsequent to initiation 
of clinical trials, riluzole proved effective in animal models of ALS (148-150), but the 
effect could not be replicated in a well-controlled study with large cohorts of mice 
(151).  
This, and the fact that many studies with positive effects in ALS animal models 
were not replicated in clinical trials, have forced those in the field to conduct better-
planned and better-controlled preclinical trials (152). 
Since no curative treatment is yet available, much effort has been put into 
symptomatic relief for the patients. Examples are listed below:  
 botulinum toxin injections and radiotherapy seem to reduce 
hypersalivation (153-155); 
 external coughing machines are useful for assistance in clearing of the 
upper airways from tenacious secretions (156); 
 treatment of malnutrition (157) with a percutaneous endoscopic 
gastrostomy (PEG) tube is used when the patient can no longer eat by 
himself/herself (158); 
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 and psychopharmaceuticals are used for treatment of sudden and 
involuntary mood swings. 
Finally, stem cell technology is often mentioned as a promising treatment 
strategy for ALS and other incurable (neurological) diseases. Several stem cell 
transplantation techniques are being tested in laboratory models of ALS, but are far 
from being ready for clinical trials (159-161). Despite the state of art, cell 
transplantation therapies are offered at high fees. A clinic in Beijing, China, offers a 
transplantation procedure of fetal olfactory ensheathing cells that, according to their 
advertisement, “can prevent or reverse the deterioration of ALS”. 
Anyway, the keystone of ALS treatment remains symptomatic (162). 
All ALS patients eventually develop respiratory insufficiency: nocturnal 
hypoventilation is usually the first sign of respiratory dysfunction and symptoms may 
negatively influence quality of life long before respiratory ensues (163). Non-invasive 
home mechanical ventilation is a treatment option for (nocturnal) hypoventilation. The 
primary objective of non-invasive ventilation is symptomatic treatment of (nocturnal) 
hypoventilation and thereby improving quality of life and prolonging survival (164). 
Today, many hospitals have special ALS care teams with, for example, 
physicians, nurses, dentists, physical therapists, speech therapists, and dieticians, all 
specialized in the care of ALS patients. These kinds of teams have been shown to 
improve survival in clinical trials (165). 
 
 
I.A.5.  Genetics of Amyotrophic Lateral Sclerosis 
The genetics of ALS is complicated and genetic risk factor has been studied 
extensively. In the ALS Online Genetic Database (166), there are currently 71 reported 
ALS-associated loci (http://alsod.iop.kcl.ac.uk/). 
In 90-95% of cases, the disease is defined sporadic (sALS), while in about 10% 
of cases the disease is familial (fALS) and patient has at least one or two first or 
second-degree relatives with the disease (167). A recent meta-analysis of 33 studies 
reporting fALS rates in different populations showed a low rate of only 5% (168). This 
percentage is probably too low due to inadequate family history, incomplete 
penetrance, misdiagnosis, and false paternity. Moreover, a recent twin study indicated 
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a genetic component also for sALS (169) and genome-wide association studies 
(GWAS) conducted on sALS patients have supported this idea (170-171).  
Familial ALS is clinically and genetically heterogeneous with multiple 
autosomal dominant and recessive forms. Dominant fALS is characterized by large 
intra- and interfamilial variability of age of onset and progression. Incomplete 
penetrance has been observed in pedigrees (172) and confirmed by mutation analysis 
(173). Before linkage analysis and molecular diagnosis of ALS through molecular 
analysis became available, autosomal recessive fALS was considered very rare; 
however, actually, at least three forms of recessive fALS are recognized. Altogether, 
the now established forms of fALS account for probably 20-30% of fALS. 
Molecular genetic analysis of fALS has led to the discovery of several genes 
involved in ALS, classified as “major genes” and “susceptibility genes” (Table 1).  
 
 
Table 1. Genetics of ALS 
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In particular, the “major genes” cause ALS with a clearly monogenic 
inheritance pattern. They may either predominantly lead to ALS (ALS1-ALS6) or 
cause multisystem neurodegeneration (tauopathies and ALS with dementia and 
parkinsonism) with ALS as an occasional symptom. The “susceptibility genes”, 
instead, may trigger the cascade of neurodegeneration or may act as susceptibility 
factors for neurodegeneration, interacting with environmental or other genetic risk 
factors.  
The “major genes” include: 
 ALS1/SOD1. In 1991, the first ALS gene (ALS1) for an autosomal dominant 
form of fALS was mapped to chromosome 21q (174), and, two years later, the 
cytosolic copper-zinc superoxide dismutase (SOD1) gene was shown to be the 
ALS1 gene (175). Actually, more than 110 different mutations in all five exons 
of SOD1 gene have been identified (176-177). All these SOD1 mutations are 
associated with autosomal dominant fALS, except two, D90A and D96N that 
can cause both dominant and recessive ALS (178-180). 
 ALS2 or Alsin. The gene for ALS2 was identified in Tunesian and Kuwaiti 
families and named alsin or ALS2 (181-183). Alternative splicing of this gene 
produces a short and a long transcripts, and deletions could affect both 
transcripts resulting in the ALS2 phenotype. Symptoms occur in the first or 
second decade of life, and include progressive spasticity of the limbs and the 
facial and pharyngeal muscles. Survival is relatively long (range from 15 to 20 
years) (184). 
 ALS3. One locus on chromosome 18q21 was found to be linked to ALS in a 
GWAS involving a large European family (185), but the gene is still unknown. 
Affected individuals suffer from adult-onset classical ALS, inherited in an 
autosomal dominant manner. 
 ALS4. A second form of autosomal dominant fALS, named ALS4, has been 
localized to a locus on chromosome 9q34 in an extended family with juvenile 
onset (mean age at onset 17 years) and slow progression without bulbar 
involvement. Later, the gene was identified as senataxin (186), and cause an 
autosomal dominant form of juvenile ALS. 
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 ALS5. The ALS5 gene was mapped to chromosome 15q and twelve sequence 
variants were detected in the spatacsin gene in 10 unrelated families (187). 
This form of autosomal recessive fALS is clinically similar to ALS2 (188). 
 ALS6. The same region on chromosome 16p12-16q21 was identified by three 
independent groups as being linked to autosomal dominant, classical adult-
onset ALS (189, 190). Later, the mutated gene was identified as fused in 
sarcoma (FUS), also known as translocated in liposarcoma (TLS) (191). About 
5% of fALS cases have been reported to carry FUS/TLS mutations and there 
is an overlap with FTD. FUS/TLS is a functional homolog of TDP-43; both 
function as DNA/RNA binding proteins. In disease, the proteins accumulate 
abnormally in the cytoplasm (192). This has led to theories about toxicity in 
ALS and FTD. 
 ALS8. A region on chromosome 20q13 was linked to fALS in a large Brazilian 
family of European descent (193). Further investigation led to the discovery of 
a point mutation in the gene encoding vesicle-associated protein B (VAPB) 
(194). Mice expressing mutant VAPB develop normally and do not develop 
motor phenotypes, but TDP-43-positive inclusions were seen at 18 months 
(195). 
 ALS10. The clinical and pathological overlap of ALS and FTD has been 
known for a long time, and families exist with persons diagnosed with ALS, 
FTD, or both in the same patient (196). Several loci have been linked to ALS-
FTD. When the intracytoplasmic inclusions in both ALS and FTD were shown 
to contain TDP-43, an intensive hunt for mutations in the gene was started. 
Soon, a number of mutations were found in families with ALS, FTD, and both. 
About 4% of fALS cases and < 1% of sALS cases carry TDP-43 mutations 
mostly without cognitive dysfunction (197).  
 
Considering that mutations in ALS genes occur in familial as well as sporadic 
ALS patients, probably more than 10% of ALS can be explained by the multiple 
autosomal dominant and recessive forms. Since there is still no evidence for any 
specific environmental cause for sporadic or familial ALS, most remaining cases of 
the disease are thought to result from interaction of several genes and environmental 
factors. In this broader complex genetic context, these genes are referred to as 
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‘susceptibility genes’ as mutations in these genes may lead only to ALS in the presence 
of other genetic or environmental risk factors. 
The “susceptibility genes” include: 
 Neurofilaments. Abnormal accumulation of intermediate filaments (IF) in the 
perikarya and proximal axons of motor neurons is a common pathological 
hallmark of ALS, suggesting that abnormalities in neurofilament organization 
may be involved in the pathogenesis of the disease (198). Neurofilaments are 
the principal intermediate filament type expressed by motor neurons. They are 
formed by the co-assembly of three subunits: NF-L (light subunit), NF-M 
(medium subunit), and NF-H (heavy subunit). NF-L is necessary for filament 
assembly, whereas NF-M and NF-H form links with other neurofilaments in 
axons (199). It is unclear whether the IF accumulations in ALS occur as a 
secondary feature of ALS associated neurodegeneration or represent the 
primary cause of disease. Several lines of evidence suggest that neurofilament 
genes play a causal role, and it seems that IF variants are likely modifying risk 
factors in sporadic ALS and probably modulate disease expression in SOD1-
related ALS (200).  
 Excitotoxicity genes. The term excitotoxicity refers to a phenomenon in which 
the excessive or prolonged activation of excitatory amino acid receptors results 
in damage and, eventually, death of the involved neurons. The activation of 
these receptors leads to depolarization and neuronal excitation and is normally 
transitory. Excitatory damage of neuronal cells appears to be mediated by 
sustained elevations of intracellular calcium levels and these excitotoxic 
mechanisms are implicated in the pathogenesis of ALS. Moreover, in the 
cerebrospinal fluid (CSF) of ALS patients, the levels of glutamate, the major 
excitatory transmitter in the motor neuron system, are increased (201), whereas 
glutamate transport is reduced in the brain and spinal cord of ALS patients 
(202). Motor neurons are vulnerable to excitotoxicity mediated by the 
glutamate AMPA receptors (203, 204) and ingestion of excitotoxins may 
contribute to the pathogenesis of the ALS-parkinson-dementia complex of 
Guam (205, 206). 
 Apolipoprotein E. The frequencies of apolipoprotein E (ApoE) ε2, ε3 and ε4 
genotypes in familial and sporadic ALS are not different from those in the 
general population (207), thereby excluding ApoE mutations as a primary 
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cause of ALS. However, the ApoE genotype was reported in some studies to 
have an effect on the age of onset and clinical presentation of sporadic ALS. 
The ε3/ε3 genotype may prolong survival in ALS patients, whereas the ε4 
allele may predict an earlier age at onset (208). However, a significantly higher 
proportion of ALS patients with the ε3/ε4 genotype had bulbar symptoms, 
while the ε2/ε3 genotype seemed to predispose to limb onset of the disease. 
Therefore, as in Alzheimer’s disease, a protective role in ALS of ε2 and ε3 
alleles, and a deleterious role of the ε4 allele have been suggested (209-211).  
The exact mechanism of the deleterious effect of the ε4 allele is unknown, but 
it may simply result from the absence of the protective ε2 and ε3 alleles. 
 Ciliary neurotrophic factor (CNTF). Reduced levels of ciliary neurotrophic 
factor (CNTF), a survival factor in spinal motor neurons, might contribute to 
the development of ALS. Indeed, it is demonstrated a decrease in CNTF levels 
in the corticospinal tract neurons of ALS patients (212) and a progressive motor 
neuron degeneration in knockout mice for CNTF (213). Finally, the frequency 
of the homozygous state for a mutation in the CNTF gene leading to absent 
CNTF is slightly increased in sporadic ALS patients (214). 
 Cytochrome P450 debrisoquine hydroxylase (CYP2D6). Protein 
polymorphisms in the cytochrome P450 debrisoquine hydroxylase gene 
(CYP2D6) are associated with Parkinson’s disease (215) and three different 
studies suggested the role of the CYP2D6 (b) allele as a risk factor for ALS 
(216, 217). In the Chamorro population, the frequency of this mutant allele was 
higher than in Caucasians, but no differences were found between healthy 
Chamorro people and patients with Guamanian ALS- dementia-parkinsonism 
complex. 
 Apurinic apyrimidimic endonuclease (APEX). The DNA repair enzyme 
apurinic/apyrimidinic endonuclease (APEX nuclease) might be a risk factor for 
ALS as reduced levels of APEX nuclease were found in the frontal cortex of 
ALS patients (218). In two different studies, it is demonstrated that APEX gene 
mutations result in a decreased level and activity of the enzyme in ALS (219-
221). APEX nuclease may also play a role in the Guamanian ALS-dementia-
parkisnonism complex, since a metabolite of cycasin, methylazoxymethanol 
(MAM), a potential environmental genotoxin in Guamanian ALS, was found 
to cause significantly reduced neuronal APEX levels and activity. Although 
Introduction ALS 
  
 22 
APEX mutations do not seem to account for a large proportion of ALS, the role 
of DNA damage in the etiology of ALS may be important. 
 Additional candidate genes. Various additional “candidate genes” for ALS as 
a monogenic entity or a multifactorial disease have been proposed. These 
candidate genes include genes involved in free radical removal, despite SOD1 
is involved in ALS through mechanisms probably not related to antioxidant 
activity. For example, the copper chaperone for superoxide dismutase (CCS), 
a cytosolic protein that mediates the delivery of copper to SOD1, seems to have 
a role in ALS (222); indeed, experiments with CCS knockout mice show a 
marked reduction in SOD1 activity (223). Another example is the monoamine 
oxidase (MAO), a generator of free radicals. Indeed, it is demonstrated the 
association with MAO-B and a later age-at-onset of ALS, suggesting a role for 
oxidative damage in ALS (224).  
A role in ALS has been proposed also for different genes. For examples, Bcl-
2 gene, encoding a protein that inhibits apoptosis, seems to attenuate 
neurodegeneration in SOD1-mediated ALS models (225); moreover, the levels 
of c-jun, a transcription factor, are increased in the spinal cords of patients with 
sporadic ALS (226, 227).  
Finally, an important role is played by the blood group phenotype P2. It is over-
represented in ALS patients (43% of U.S. veterans with ALS, more than twice 
as frequent as expected) (228), and appears extremely frequent (66%) in the 
indigenous Chamorros of the islands Guam and Saipan (229). Close structural 
similarity of P2 to GM1 ganglioside may explain the characteristic 
immunologic features of ALS patients, such as the increase in IgM antibodies 
against GM1 ganglioside by cross-reactivity against the P-system blood group 
antigens (230). 
Other genes that might involve predisposition to ALS are the interleukin-2 
receptor beta chain gene, localized to the chromosome 22q11.2-q12, which is 
a locus for many neodysplasias of the lymphoid system, and the leukemia 
inhibitory factor gene (LIF) on chromosome 22q12.1-q12.2 (231). Recently, 
knockout mice for the hypoxia-response element (HRE) of the vascular 
endothelial growth factor (VEGF) gene were shown to develop an ALS-like 
condition, but VEGF mutations have not yet been identified in human ALS 
(232). 
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I.A.6. Pre-clinical models used to study Amyotrophic Lateral 
     Sclerosis 
The exact mechanisms by which all the above described gene products are 
involved in ALS pathogenesis are the subject of many ongoing researches. Different 
studies have identified some involved cellular pathways, including protein misfolding, 
RNA processing, oxidative stress, excitotoxicity, axonal transport, mitochondrial 
dysfunction and abnormal secretion of proteins.  
In the attempt to clarify the molecular mechanisms that lead to ALS, many 
different in vitro and in vivo models are developed to study the disease.  
In vitro models are extremely helpful to study human diseases, because they 
allow to analyze different cell types independently from each other and to perform 
dynamic studies on isolated cells. Moreover, diseased cells can be combined with 
healthy ones to better understand which cell type is the most critical in the different 
stages of the disease.  
In vivo models, similarly, are extremely useful because animal models replicate 
human disease. Nevertheless, how accurately animal models replicate all ALS human 
clinical symptoms remains an unanswered and troublesome question.  
 
I.A.6.1 In vitro models 
Some in vitro models developing to study ALS deriving from animal models. 
Indeed, neural cells are impossible to obtain from patients and their extraction from 
post-mortem tissues is limited due to the difficulty to isolate living cells from adult 
brain or spinal cord, especially motor neurons. However, such post-mortem tissue 
biopsies are mostly used to perform histological and immunohistochemical, genetic 
and proteomic studies.  
The most used in vitro models useful to study ALS include: organotypic 
cultures, spinal cord cell cultures, NSC-34 motor neurons, Xenopus oocytes, and 
neuronal precursor cells. More recently, three-dimensional in vitro models are 
developed to study the disease.  
Organotypic slices could be obtained from the spinal cord of embryos and post-
natal animals. (233, 234). These cultures could be used for more than 2 months (235) 
to reproduce the in vivo situation perform various analysis. Indeed, organotypic slices 
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are useful for dynamic studies with different drugs, for immunohistochemical staining 
and electrophysiological recordings (236, 237).  
A valid alternative is represented by spinal cord cell cultures, isolated from 
E12-14 mice embryonic developmental stage. At this stage, the spinal cord of mice 
embryos is easy to remove and motor neurons, astrocytes and microglia can be 
extracted and maintain in culture (238, 239). Motor neurons will be easy to identify 
because of their large cell body (>20µm in diameter) and dendritic trees, and can be 
stained for expression of typical markers, such as choline acetyltransferase (240, 241). 
The isolation of individual cells is extremely useful to study various intracellular 
mechanisms from proliferation to mRNA expression, mitochondrial function, protein 
aggregation, intermediate filament assembly or axonal transport. 
However, neurons cannot proliferate, and, thus, it is necessary to perform cell 
extraction from embryos for each new experiments. Moreover, primary neuron 
cultures are difficult to maintain in culture for more time and cells cultured on plastic 
dishes cannot recapitulate the in vivo environment.  Furthermore, another disadvantage 
to use primary cells from embryos is that some features of the adult phenotype may 
not be expressed at this early stage (242). 
To greatly facilitate in vitro studies, motor neuron-enriched embryonic mouse 
spinal cord cells were fused with mouse neuroblastoma to generate the hybrid cell line 
NCS-34 (243). This cell line contains small proliferative and undifferentiated cells and 
larger multinucleate cells. These cells express properties of motor neurons, such as 
choline acetyltransferase, acethylcholine synthesis and neurofilament expression. 
They respond to agents affecting voltage-gated ion channels, cytoskeletal organization 
and axonal transport similarly with primary motor neurons, but failed to reproduce 
synaptic connections (244).  
To reproduce an ALS phenotype, primary and secondary motor neurons can be 
induced to express multiple copies of the gene of interest or can be exposed to L-
BMAA to reproduce the Guam form of ALS. Moreover, NSC-34 motor neurons are 
useful to study cellular morphometry (axon length), gene expression using RT-PCR, 
apoptosis, signaling pathways, calcium imaging, mitochondrial membrane potential, 
glutamate uptake, excitotoxicity, and to screen antioxidant molecules capable of 
rescuing them from expression of mutated SOD1 (245). 
For electrophysiological recording, the oocyte of Xenopus Laevi, an African 
frog, are useful because of its large size (about 1 mm in diameter) which facilitates its 
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handling. The oocytes, usually, are used to study various ion channels, transporters 
and receptors. In studies related to ALS, for examples, oocytes are used to analyze ion 
channels or transportes, such as the human glutamate transporter GLT1 (EAAT2), 
under controlled voltage clamp in presence or not of mutant SOD1 (256). 
The described in vitro model are particularly useful to study familial ALS, 
because, it is possible induce in each model the expression of a gene with a mutation 
that reproduces ALS. To study sporadic ALS, in which the mutation is unknown, 
instead, mouse embryonic stem cells (ESCs) or neuronal precursor cells (NPCs), 
which can be extracted from adult tissues, are more useful. Indeed, the potential of 
mouse ESCs to differentiate into motor neurons has been well established (257). Thus, 
it is possible to obtain ESCs from easily accessible tissues, such as skin (258), and to 
induce their differentiation into motor neurons. Moreover, neurons, astrocytes and 
oligodendrocytes could be differentiated from NPCs purified from familial and 
sporadic ALS patient post-mortem spinal cord samples. These cultures are useful, for 
example, to study the toxic properties of patients-derived astrocytes on motor neurons 
(259).  
A good alternative to ESCs and NPCs is represented by the induced pluripotent 
stem cells (iPS cells), obtaining from somatic cells. To obtain iPS cells, a small biopsy 
of a few millimeters in diameter collected from the patient’s skin is required. From 
this biopsy, dermal fibroblasts will be extracted and expanded to generate iPS cells. 
Other methods to reprogram cells are now being intensively tested, such as the use of 
secreted recombinant reprogramming factors present in the culture media. The iPS 
cells are morphologically and phenotypically similar to ESCs, and, thus, it is possible 
to obtain motor neurons starting to the IPs cells (260, 261). Actually, it is not clear 
whether motor neurons and glial cells derived from ALS patients-iPS cells will 
efficiently recapitulate the disease in vitro, because the technology is still recent.   
Finally, more recently, motor neurons derived from iPS cells or NPCs ALS 
patients are used to develop three-dimensional in vitro models of ALS. For examples, 
these cells have been cultured on methylcellulose scaffold enriched with laminin and 
they showed reduction of apoptosis, enhance of survival, differentiation in neuronal 
and glial cells and neurite extension (262, 263). Thus, the combination of ALS patient 
NPC-derived neural cells in tissue-engineered reconstructed spinal cord models is a 
promising strategy to develop the next generation of in vitro models of ALS. 
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I.A.6.2 In vivo models 
Actually, different invertebrate and vertebrate animals are used to obtain in 
vivo models able to reproduce ALS and the human features of the disease. Each model 
organism, of course, has its own advantages and disadvantages and the choice of an 
appropriate model depends on the investigated question. For this cause, often, it is 
useful to perform experiments in two or more model systems to better characterize 
different aspects of the disease. Moreover, in this way, it is possible to reproduce 
human disease.  
Invertebrate model organisms include the simple yeast (fungi), fly, and 
nematode. These model organisms have highly manipulable genomes allowing for 
rapid generation of transgenic lines to provide insight on gene functions and protein 
network interactions. The obvious disadvantage of using invertebrate model organisms 
is that they are evolutionarily far from mammals and that many physiological functions 
are not conserved. Furthermore, their organs are extremely undeveloped and simple 
compared to other animals. The limited cellular diversity also represents a major 
disadvantage. 
Actually, different ALS models are obtained in C. elegans. The first ALS 
model was obtained by introducing human wild type and various fALS SOD1-linked 
mutations (A4V, G37R and G93A). Moreover, in order to study TDP-43 function and 
neurotoxicity, transgenic C. elegans model was generated allowing pan-neuronal 
expression of the wild-type TDP-43 human protein (264). Obviously, the nematode is 
a too simpler organism unable to reproduce a human disease; however, several 
investigations using these models may reveal insights into SOD1 and TDP-43 
functions, potentially reveal neurotoxic mechanisms relevant to ALS and other 
neurodegenerative diseases, and ultimately lead to the development of novel 
therapeutic targets. 
The fruit fly Drosophila melanogaster is a powerful genetic tool to study 
neurodegenerative diseases, because Drosophila is a complex organism, with a 
functioning brain and nervous system, capable of many behaviors, like learning, 
motility, and visual acuity. In the context of ALS, D. melanogaster is used to obtain 
SOD1, TDP-43 and FUS transgenic models. These models mimic human disease: for 
example, SOD1-mutated flies show progressive motor dysfunction, 
electrophysiological defects and abnormal accumulation of SOD1 and stress respond 
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in surrounding glial cells (265). Studies in TDP-43-mutated D. melanogaster, instead, 
support the notion that loss of normal TDP-43 function may contribute to the 
pathogenesis of ALS and FTLD. Moreover, ubiquitous or tissue-specific 
overexpression of human TDP-43 also recapitulated key hallmark features of ALS 
pathology, including premature lethality, neuronal loss, neuromuscular junctions 
architecture defects and locomotor deficits. (266, 267). Finally, FUS/TLS transgenic 
flies show locomotor dysfunction and premature lethality; the overexpression of 
mutant FUS/TLS, instead, caused an accumulation of ubiquitinated proteins, a 
pathological hallmark of ALS. 
Invertebrate model organisms, however, are too simple to reproduce a human 
disease. The use of vertebrate models, instead, offer the best opportunity to define 
landmarks of disease progression and to understand the functional consequences of 
gene mutations. The great advantage of using vertebrates to model human diseases is 
clearly the possibility they offer for evaluation of new treatments. Indeed, testing new 
drugs on mice or other vertebrate models is often mandatory and asked by the Food 
and Drug Administration, for safety reasons, prior to approve new drug treatments. 
This step is also fundamental for paving the way towards human clinical trials, with 
both larger and smaller vertebrate model organisms. Other advantages of using 
vertebrate models include: 
 the ability to make efficient targeted gene knockouts by homologous 
recombination; 
 they are evolutionary closer to human; 
 the developmental overview is similar for all mammals; 
 the availability of material at all stages of development; 
 their brains are more similar to human; 
 they respond to injury and can be conditioned, great advantages to study 
learning, neuronal connectivity and plasticity; 
 and they provide a valuable source of primary cells for culture. 
On the contrary, the high maintenance cost, a relatively slow life cycle 
development, lower number of progeny, genetically identical offspring more difficult 
to obtain and the difficulty to manipulate embryos (intrauterine development) 
represent the major disadvantages of using vertebrate as disease model organisms. 
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The main vertebrate models used to study ALS are mice, rats, zebrafish, dogs 
and pigs. Obviously, in the laboratories, mice and rats represent the most used animal 
models.  
Over the past century, the mouse Mus musculus has become the premier 
mammalian model organism for experimental studies and genetic research, because of 
its close genetic and physiological similarities to humans, as well as the ease with 
which its genome can be manipulated and analyzed, ease of handling and relatively 
high reproductive rate. There are many mouse models commercially available for 
genetic research, including thousands of unique inbred strains and genetically 
engineered mutants.  
The use of mouse models has been of particular importance in studying the 
pathogenesis of ALS. The initial description of SOD1 gene mutations in familial ALS 
patients, in 1993, first led to the hypothesis that the disease resulted from compromised 
enzymatic activity due to the loss of the enzyme function (268). However, this loss of 
function hypothesis was rapidly refuted, because SOD1 knockout (KO) mice do not 
develop disease (269). In contrast, transgenic mice ubiquitously overexpressing 
various SOD1 gene mutations with different biochemical properties, even in the 
presence of endogenous mouse SOD1 gene, develop a neurodegenerative disease that 
is quite similar to the human illness. Of particular interest, transgenic mice 
overexpressing wild type human SOD1 or specifically expressing mutant SOD1 only 
in neurons or only in glial cells do not develop disease (270, 271).  
Although more than 150 mutations in SOD1 are known and many transgenic 
mice are developed, the SOD1G93A mouse is, currently, the most widely used 
experimental model in ALS research and drug testing. Unlucky, several 
pharmacological approaches tested so far have produced only modest beneficial 
effects. Riluzole, a glutamate antagonist and the only drug useful for ALS treatment, 
extended the life span of SOD1G93A mice by 10 to 15 days without affecting disease 
onset (272). This mouse model, thus, is useful to test new drugs potentially useful for 
ALS treatment. For example, it has been shown that treatment with the endoplasmic 
reticulum (ER) stress-protective agent salubrinal attenuated disease manifestations and 
delayed progression in a SOD1G93A mouse model (273), suggesting a role of ER stress 
in ALS.  
Other mouse models useful to study ALS are mice TDP-43 models, mice 
intermediate filament models, and mice ALS2 models. 
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Embryonic lethality is observed in homozygous mouse knockouts for TDP-43 
(274, 275). The TDP-43 deficient embryos die at embryonic day 7.5, thereby 
demonstrating the essential function of TDP-43 protein in development. Mice 
heterozygous for TDP-43 disruption only exhibit subtle muscle weakness with no 
evidence of motor neuron pathology. However, many of the transgenic mouse lines 
overexpressing wild type or mutant TDP-43 reported to date have showed some ALS 
features, including early paralysis leading to premature death (276, 277). 
Several transgenic mouse lines and knockout mice implicating different 
neurofilament subunits have been extensively studied over the past years (278). Even 
though genetic mutations in intermediate filament (IF) genes are not major causes of 
ALS, it is of potential relevance to ALS that transgenic mice with altered stoichiometry 
of neuronal intermediate filament develop pathological features of the disease (279, 
280). Of particular interest was the finding that overexpression of wild type peripherin, 
a type III intermediate filament, in NEFL knockout mice caused age-dependent 
selective motor neurons degeneration (281). This mouse model is also characterized 
by the formation of perikaryal and axonal intermediate filament inclusions resembling 
spheroids in motor neurons of human ALS. The precise mechanism by which 
accumulation of intermediate neurofilament leads to neurodegenerative disorders is 
not fully understood. Neurofilament and peripherin proteins are two types of 
intermediate filaments detected in the majority of axonal inclusion bodies, called 
spheroids, in motor neurons of ALS patients (282). Multiple factors can potentially 
cause the accumulation of intermediate filament proteins, including de-regulation of 
intermediate filament protein synthesis, proteolysis, defective axonal transport, 
abnormal phosphorylation, and other protein modifications. 
Finally, six different groups have reported the generation of an alsin knockout 
mouse (283, 284). Despite an age dependent loss of motor coordination revealed by 
rotarod and grip strength performances of the ALS2 KO mice, no major motor deficits 
consistent with ALS or other motor neuron diseases were present in these models. All 
ALS2-deficient mice appear to be grossly normal, viable and fertile with lifespan 
expectancy similar to wild type littermates. However, some differences are noteworthy 
and may explain the heterogeneity of the phenotype. The diversity of the apparent 
phenotypes among different ALS2 KO mouse models may be due in part by different 
gene targeting strategies used to generate each mouse models, ES cell lines used 
leading to differences in the genetic background, housing conditions or approaches 
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taken to evaluate the mice. Interestingly, thorough molecular analysis of one of these 
ALS KO mouse model revealed the presence of a number of novel ALS2 isoforms 
expressed in the central nervous system of these animals (285). These results suggest 
that other alternatively spliced ALS2 isoforms may exist and that some of these novel 
ALS2 mRNA species still can be transcribed in ALS2 knockout animals and may 
compensate for the loss of the full-length protein. 
The rat Rattus norvegicus offers some advantages over the mouse and the other 
organisms. First, rats are physiologically more similar to humans compare to mice. 
The size of the animal also confers a valuable advantage and enhances its use as a 
disease model. For example, the size of the rat brain offers unique possibilities for the 
application of microsurgical techniques, intrathecal administration of drugs, stem cell 
transplantation, serial sampling of the cerebrospinal fluid (CSF), in vivo nerve 
recordings, and neuroimaging procedures. However, even though its size is considered 
as an advantage over mice, the higher cost of maintenance (bigger cages, food, less 
animals can be housed per cages) and limited housing capacity in animal facilities 
directly related to its size also confers the principal limitation of using rats as a model. 
Transgenic rat models of ALS have also been generated, including SOD1 
transgenic rats and TDP-43 transgenic rats.  
In rats, overexpression of G93A or H46R mutant SOD1 led to an ALS-like 
phenotype (286). These transgenic rat models reproduce the major phenotypic features 
of human ALS, such as selective motor neuron loss, ubiquitination, hyaline inclusions, 
vacuolation, and neuroinflammation. However, several differences between the rat and 
mouse ALS models can be denoted, including a more rapid progression of disease and 
the transient appearance of vacuoles in the transgenic SOD1 rats.  
Moreover, in rats, the overexpression of mutant TDP-43 only, but not the wild 
type protein, caused widespread neurodegeneration, in contrast to what observed in 
mice. The transgenic mutant TDP-43 rat model exhibited progressive degeneration of 
motor neurons, neurodegeneration was not only restricted to motor neurons. However, 
TDP-43 mutation affected motor neurons earlier and more severely than other neurons 
in the CNS at end stage of the disease. However, this rat model mimic TDP-43 
pathological features both seen in the different mouse models and in ALS patients, 
indicating that this model could be used in future pharmalogical studies in order to 
identify novel therapeutic avenues to treat TDP-43 related disorders. 
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I.B.  Superoxide dismutase 
The superoxide dismutase (SOD) belongs to a metal-protein family that 
catalyzes the dismutation of superoxide anion (O2-) in molecular oxygen (O2) and 
hydrogen peroxide (H2O2) (fig. 4). Thus, SOD plays a key role in the antioxidant 
defense of organisms against toxicity induced by reactive oxygen species (ROS).   
 
 
 
Figure 4. Dismutation of superoxide anion 
 
 
The name of the protein derives from its discovery; indeed, about 50 years ago, 
copper was associated with hematic and hepatic proteins, named erythrocuprein and 
hepatocuprein (287). Then, in 1969, Fridovich and McCord discovered the activity of 
SOD by studying the reduction of cytochrome c (288).  
Actually, different isoforms of SOD are known: they are proteins cofactored 
with copper and zinc, manganese, iron or nickel (289, 290). Thus, there are three major 
families of superoxide dismutase, depending on the metal cofactor: Cu,Zn, which 
binds both copper and zinc, Fe and Mn isoenzymes, which bind either iron or 
manganese; finally, another family of SOD uses Ni as cofactor. These families of 
enzymes are different for localization, distribution and specie-specificity (291).  
 The discovery of SOD and its function has important physiological 
implication; indeed, superoxide anion is produced by the metabolism of molecular 
oxygen and its half-life is very brief, because superoxide anion reacts with different 
organic molecules and causes their oxidation. Thus, SOD represents the first defense 
mechanism against ROS in all aerobic organisms.  In this context, in 1979, Mc Cord 
suggested an enzyme-based theory of obligate anaerobiosis: the aerobic existence of 
an organism depend on its capability to produce SOD; thus, an organism lacking SOD 
could survive only in anaerobic environment (292). However, other evidence suggests 
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a tolerance range, defined as maximum amount of atmospheric oxygen that allows the 
survival of anaerobic organisms lacking SOD (293). 
 
 
I.B.1. Isoforms of superoxide dismutase 
The superoxide dismutates are metal-enzyme containing a metal-ion (copper, 
iron or manganese). The genes that code for the three major families of SOD derive 
by two not correlated ancestral genes: from one gene derives the families of Fe-SOD 
and Mn-SOD, diffused in aerobic organisms, from bacteria to plants and humans. 
From the other gene derives the family of Cu,Zn-SOD, diffused only in eukaryotes. In 
table 2, the main characteristics of the different isoforms of SOD are represented.  
Today, it is known the cellular distribution of the different isoforms of SOD: 
Cu,Zn-SOD (SOD1) is the eukaryotic cytosolic isoenzyme; Mn-SOD (SOD2) is 
located in the mitochondrial matrix of some eukaryotes and mammals; Fe-SOD is 
located in the cytosol of prokaryotes and some eukaryotes. Finally, the EC-SOD 
(extracellular SOD or SOD3) is located at extracellular level (fig. 5). In humans, there 
are three isoforms of SOD: SOD1, SOD2 and SOD3.  
However, exceptions to this general rule exist; for example, some prokaryotes 
express the Cu,Zn-SOD (294-296); moreover, the Mn-SOD is the mitochondrial 
isoform in mammals, but in humans it is the main isoform located in the cytosol of 
hepatic cells.  
 
 
Name Molecular weight Structure Localization Distribution 
Cu,Zn-SOD 32,000 Dimeric Cytosol Eukaryotes/ 
Prokaryotes 
Mn-SOD 40,000 - 
80,000 
Dimeric – 
tetrameric 
Cytosol, 
mitochondria   
Mammalians 
Fe-SOD 40,000 - 
80,000 
Dimeric - 
tetrameric 
Cytosol, chloroplast, 
mitochondria  
Prokaryotes 
Table 2. Molecular weight, structure, localization and distribution of the three isoforms of 
SOD. 
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Figure 5. Isoforms of SOD and their localization  
 
 
I.B.1.1. Mn-SOD and Fe-SOD 
The molecular structure of Mn-SOD (fig. 6) and Fe-SOD (fig. 7) are not well-
defined as the molecular structure of Cu,Zn-SOD; indeed, it is known only the primary 
structure of four Mn-SOD (297-299), while it is known eleven primary structures of 
Cu,Zn-SOD (300-302). Moreover, the complete aminoacid sequence of Mn-SOD is 
yet unknown.  
The isoenzymes containing iron and manganese show molecular subunits of 
about 23.000 Dalton: the Fe-SOD exists only as dimer, while the Mn-SOD could exist 
as dimeric or tetrameric enzyme (303). These isoforms could contain one or two atoms 
for dimer and this difference, maybe, is caused by the loss of metal during purification 
processes. The crystallography analysis about Fe-SOD suggests two binding sites for 
metal (304). In addition, the ligands of manganese are localized in the same position 
of Fe-SOD (305), and many evidence indicate that Mn-SOD and Fe-SOD are 
structurally homologous (306). 
Since the little knowledge about these two enzymes, the reaction mechanism is 
similar to the reaction catalyzed by Cu,Zn-SOD. However, the exact catalytic activity 
is not completely known, because Mn-SOD and Fe-SOD are not structurally correlated 
with Cu,Zn-SOD.  
The catalytic activity follows the same general scheme of Cu,Zn-SOD, because 
it involves the couples Fe3+/Fe2+ and Mn3+/Mn2+. Moreover, for the Mn-SOD, it is 
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hypothesized that catalytic activity is involved in the production of final species (307, 
308) and the catalytic efficiency is lower rather the catalytic efficiency of the other 
SOD.  
 
 
 
Figure 6. Binding site for metal of Mn-SOD 
 
 
 
Figure 7. Three-dimensional structure and binding site for metal of Fe-SOD. 
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I.B.1.2. Cu,Zn-SOD 
Cu,Zn-SOD (SOD1) (fig. 8) is a dimer of about 32.000 Dalton, located mainly 
in the cytosol of eukaryotes. The two identic subunits are composed of 153 aminoacids 
with a theoretical molecular weight of about 16 kDa, and are associated with not-
covalent interaction and each one contains 1 g for atom of copper and zinc. The two 
ions are binding by an imidazole ring of a histidine of the protein.  
The gene coding for SOD1 in humans is located on the long arm of 
chromosome 21 at 21q22.11, and, today, it is well-characterized (309). The gene is 11 
kb long and has five exons and four introns (310). The main transcript can be both 0.7 
kb and 0.9 kb, due to different polyadenylation at the 3’ end. Additional splice forms 
have be found (311): these alternative splice forms are unstable and may be 
immediately degraded.  
The three-dimensional structure of bovine SOD1 from erythrocytes was solved 
in 1982 (310), and many different structures of SOD1 variants have been solved both 
by nuclear magnetic resonance (NMR) and by X-ray crystallography. The first human 
SOD1 structure was solved ten years later (312).  
Immunocytochemistry analysis and cellular fractionation confirm the cytosolic 
localization of SOD1 in same different cell lines. Moreover, SOD1 is located also in 
different subcellular compartments, such as nucleus, lysosomes, mitochondrial 
intermembrane space, endoplasmic reticulum and Golgi apparatus (313).  
 
 
 
Figure 8. Three-dimensional structure of SOD1. 
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The dismutation reaction follows two step at the same speed: in the first step, 
the superoxide anion is reduced in molecular oxygen with the reduction of Cu2+ to Cu+; 
in the second step, hydrogen peroxide is reduced by another superoxide anion and, in 
this way, the catalytic site is regenerated (fig. 9).   
The enzymatic function was assigned to copper bound to the enzyme, since all 
activity was lost upon removal of metal. Instead, the zinc ion is needed for structural 
stability of the protein.  
The exact catalytic mechanism was determined by pulsate radiolysis analysis 
and, then, it is confirmed for Mn-SOD and Fe-SOD (314).  
 
 
 
Figure 9. Catalytic reaction of SOD1 
 
 
SOD1 is expressed in almost all eukaryotic cells at high levels and it is also 
found in some bacteria (294-296). In humans, SOD1 is mainly located in the liver and 
in the kidneys; in the central nervous system, that is affected in ALS, SOD1 
expression, instead, is lower (315-316). In particular, immunohistochemistry analysis 
reveal the expression of SOD1 in spinal cord: the most intense staining was found in 
the ventral horn.  
SOD1 is mainly a cytosolic enzyme (317), but some SOD1 could be found in 
other cellular compartments: for example, it is found in the mitochondrial 
intermembrane space (318), where the high production of superoxide during oxidative 
phosphorylation requires SOD1 and SOD2 (that is the main mitochondrial isoform). 
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In addition, SOD1 has also been found in the nucleus of different cell types and in 
body fluids, such as serum and cerebral spinal fluid (CSF) (319, 320).  
 
 
I.B.2. Secretion of Cu,Zn-superoxide dismutase 
Since SOD1 is considered a constitutive enzyme located in the cytosol, recent 
evidence indicate that SOD1 could be secreted in different cell lines (321) through 
microvesicles. In particular, the secretion mechanism is an ATP-dependent process; 
indeed, it is inhibited by brefeldin-A, 2-deoxyglucose and sodium azide, drugs that 
reduce intracellular pool of ATP (322). 
Thus, SOD1 could have a protective role against oxidative stress, and this 
effect could be important in the nervous system, where a high oxidative metabolism 
generates a great amount of ROS. In addition, it is demonstrated that neuronal cells 
secrets SOD1 in absence of oxidative stress. Thus, this secretion could have a paracrine 
modulatory action on neurons.  
SOD1 export in neuronal cells involves vesicles located in cytosol and 
dendrites and needs on SNARE (solubile NSF (N-ethylmaleimide-sensitive fusion 
protein) attachment protein receptor) complex activation. Indeed, it is demonstrated 
that the pre-incubation of rat adenohypophysis GH3 cells with the botulin toxin 
(BoNT/A), that cleaves SNAP-25 (323), inhibited SOD1 release.  
Finally, SOD1 release was observed in basal condition and after depolarization 
mediated by high potassium concentration (324), and cytometry analysis reveals that 
SOD1 could bind cellular membrane of neuronal cells (325).  
 
 
I.B.3. Transductional effects of Cu,Zn- superoxide dismutase 
Western blotting analysis and cytometric experiments indicate that SOD1 is 
able to induce the activation of PLC (phospholipase C)/ PKC (protein kinase C) 
pathway in human neuroblastoma SK-N-BE cells through an increase of intracellular 
Ca2+ concentration (325). The increase of intracellular Ca2+ concentration is partially 
reduced by free Ca2+ in the culture medium. Thus, it is hypothesized that this increase 
involves intracellular Ca2+ stores. 
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In addition, ω-conotoxin and L-nimodipine, that are respectively an N-type and 
L-type voltage-dependent calcium channels inhibitors, partially inhibits Ca2+ increase, 
suggesting the involvement of voltage-dependent calcium channels (VGCCs) in 
intracellular Ca2+ concentration increase induced by SOD1 (326).  
The activation of PLC/PKC pathway is independent on catalytic activity of 
SOD1, because this pathway is activated also by ApoSOD, the enzyme lacking 
catalytic activity, while mimetic drugs of SOD1, such as MnTMPyP, fail to have the 
same effect. Moreover, the pre-incubation of neuronal cell with U73122, a PLC 
inhibitor, completely inhibits PLC activation by SOD1 (325).  
Finally, in the last few years, it is reported that SOD1 is able to induce the 
phosphorylation of kinases downstream PLC/PKC pathway, such as p-ERK1/2 and p-
Akt (327).  
Thus, SOD1 is not only a scavenger of ROS, but it could be involved in other 
biological functions related to intracellular Ca2+ concentration dependent on ERK1/2 
and Akt activation.  
 
I.B.3.1. MAP kinases activation  
MAP kinases (MAPK, mitogenic-activated protein kinases) belong to a family 
of ubiquitous proline-directed, protein-serine/threonine kinases, which are involved in 
signal transduction pathways that control intracellular events, including major 
developmental changes in organisms, and apoptosis (328). The serine-threonin kinase 
ERK1/2 (extracellular signal regulated kinase) belongs to this family (fig. 10).  
ERK1 and ERK2, in particular, are proteins of 43 and 41 kDa that are nearly 
85% identical overall, with much greater identity in the core regions involved in 
binding substrates (329-331). The two phosphoacceptor sites, tyrosine and threonine, 
which are phosphorylated to activate the kinases, are separated by a glutamate residue 
in both ERK1 and ERK2 to give the motif TEY in the activation loop (332). Both the 
kinases are ubiquitously expressed and requires, for their activation, three upstream 
families of kinases, named Ras, Raf, and MEK (MAP kinase extracellular signal 
regulated kinase). 
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Figure 10.  Schematic representation of the structure of MAPK pathways: (a) General 
MAPK pathways; (b) the ERK pathway in particular (Kolch W., 2000). 
 
 
All the developmental signals able to induce MAPK activation are transmitted 
by specific receptors, such as tyrosine-kinase receptors (RTKs), cytokines receptors, 
and G-protein coupled receptors. These receptors, in particular, induces the activation 
of Ras, a small GTPase that acts as molecular switch in the transductional signal 
cascade of MAPK. After activation, indeed, Ras switches from its inactivated state 
bound to GDP (guanosine diphoshapte) to its activated state bound GTP (guanosine 
triphosphate). The first effectors of Ras is a protein-kinase belong to Raf family, 
named Raf-1. This protein is able to bind Ras in a GTPasic dependent manner: activate 
Ras binds Raf-1 and causes its translocation in membrane, where Raf-1 is activated 
(333). Then, Raf induces MEK phosphorylation through MEK kinase (MEKK) (334, 
335). Finally, MEK induces ERK1/2 phosphorylation on the acceptor sites, 
represented by threonine and tyrosine residues (335). After phosphorylation, ERK1/2 
translocates in the nucleus and induces the activation of several transcription factors.  
 
I.B.3.2 PI3K/Akt activation   
The serine/threonine kinase Akt, also named protein kinase B or PKB, belongs 
to the cAMP-dependent protein kinase A/protein kinase G/ protein kinase C (AGC) 
Introduction SOD1 
  
 40 
super family of protein kinases that show structural homology within catalytic domain 
and have similar activation mechanism (336, 337) (fig. 11).  
 
 
 
Figure 11. PKB/Akt activation downstream of RTKs via the P13K pathway (Hemmings 
B.A., 2012). 
 
 
There are three isoforms of Akt, named Akt1, Akt2, and Akt3, with a conserved 
domain structure, represented by an amino terminal pleckstrin homology (PH) domain, 
a central kinase domain, and a carboxyl terminal regulatory domain with hydrophobic 
motif. The PH domain interacts with membrane lipid products, such as 
phosphatidylinositol (3,4,5) triphosphate (PIP3) produced by phosphatidylinositol-3-
kinase (PI3K). Thus, Akt is the downstream kinase of PI3K, activated by tyrosine 
kinases receptors (RTK) or G-protein coupled receptors (338). In particular, PIP3 does 
not activate Akt directly, but induces Akt traslocation to the plasma membrane causing 
the alteration of its conformation and following the phosphorylation by 
phosphoinositide-dependen kinase-1 (PDK1).  
The activation of Akt depends on site-specific phosphorylation: the main sites 
of phosphorylation are threonine 308, activated by PDK1 (339), and serine 473, 
activated by a mechanism yet unknown. It seems that serine 473 phosphorylation site 
could be autophosphorilated (340) or phosphorylated by other kinases, such as 
integrin-linked kinase (ILK) (341).   
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The activation of Akt is also regulated by a phosphatases, such as PTEN 
(phosphatase and tensin homolog), which removes phosphate from the 3-OH position 
(342), causing the inactivation of Akt. 
Akt plays a key role in the signal transductional pathways, because it is 
involved in metabolism, cell growth, trasncritional regulation and cell survival (343).  
 
 
I.B.4. Cu,Zn-superoxide dismutase and Amyotrophic Lateral 
Sclerosis 
In 1993, a link between SOD1 and fALS was found for the first time. Today, 
more than 150 mutations in the gene coding for SOD1 associated to ALS are described 
and reported in the ALS Online Genetic Database (ALSOD). Obviously, not all 
described mutations in SOD1 are necessary pathogenetic (344), but these studies 
reveal anyway that SOD1 is extremely sensitive to mutation.  
The ALS-linked mutations are located all over the aminoacid sequence of 
SOD1, and they are found in the five exons of the gene. Most of these mutations are 
single aminoacid exchanges, but insertions and deletions are also described.  
The discovery of a link between SOD1 and ALS first suggest that oxidative 
stress could have a key role in the pathogenesis of the disease: indeed, it was 
hypothesized a loss of function of SOD1, one of the most important enzymes involved 
in the defense against ROS. 
Actually, it is known that mutations in SOD1 are associated with a gain of toxic 
function rather than a loss of function. Indeed, most of the mutant SOD1, such as 
SOD1D90A, SOD1G93A and SOD1G41D (345, 346), preserve catalytic activity, and SOD1 
mutations usually are inherited in a dominant way (347, 348), preserving at last 50% 
of enzymatic activity. In addition, transgenic overexpression of SOD1 in mice 
generates an ALS phenotype (349, 350), while SOD1 knock-out mice do not develop 
the disease (351). Finally, mutated SOD1 aggregates in the cytosol, at level of 
endoplasmic reticulum and Golgi apparatus (352), causing mitochondrial dysfunction, 
ER stress and motor neuronal death.   
Since mutations in SOD1 are associated with about the 20% of cases of fALS, 
recent evidence suggests an important role for SOD1 both in fALS and in sALS. 
Indeed, inclusions containing misfolding SOD1 are found in the CNS of both sALS 
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and fALS patients without SOD1 mutations (353), and there are evidence for soluble 
misfolded SOD1 in the spinal cord of sALS patients. Interestingly, it has been recently 
reported that wild type (wt) SOD1 can acquire properties of ALS-linked mutant SOD1 
species, indicating a shared pathophysiological pathway between sALS and fALS 
(354). Other studies showed that wt SOD1 may acquire toxic properties upon oxidative 
damage and that wt SOD1 expression dramatically exacerbated disease in transgenic 
mice expressing mutant SOD1 forms, such as SOD1A4V, SOD1G85R, SOD1L126Z, and 
SOD1G93A  (355).  
SOD1 is one of the most stable proteins known; thus, several researches has 
been tried to explain the involvement of misfolded SOD1 in neurodegenerarion. The 
aggregates found in ALS patients with SOD1 mutations are immunoreactive for SOD1 
and are a hallmark of the disease. Moreover, in control patients a SOD1 strains is 
observed diffusely in the cytoplasm, indicating that SOD1 is involved in the 
pathogenesis of ALS and, maybe, the enzyme loses its structure. In addition, nine 
mutations cause premature stop codons generating a pathogenic truncated SOD1, as 
observed in transgenic mice with truncated variants that develop ALS (356). 
Moreover, when SOD1 loses its post-traslational modification, the enzyme lost its 
stability, becoming one of the most unstable proteins (357). Mutations could affect 
SOD1 stability and folding in different ways. For example, the location of the mutated 
residue and how different chains side are between the normal aminoacid and the 
aminoacid introduced by mutation affect the stability; moreover, most mutation could 
destabilize the Apo state (358, 359). A common way to form aggregates of SOD1 is 
represented by disulfide crosslinking. SOD1 has four cysteinse (360, 361) and all these 
aminoacids have been found to be mutated in ALS patients (362, 363). Anyway, SOD1 
is not sensitive to aggregation compared to other proteins involved in 
neurodegeneration, but particular conditions, such as low pH and reducing condition 
(364, 365) could induce SOD1 aggregations.  
Thus, how SOD1 misfolding and aggregation is toxic to motor neurons is yet 
unknown. It is possible that the expression of mutant SOD1 in motor neurons will be 
not sufficient to cause degeneration, suggesting the expression of mutated SOD1 in 
other neuronal cells to develop the disease. This hypothesis, however, does not explain 
the involvement of misfolding and aggregates. The misfolded SOD1 could interact 
with other important proteins or could impair SOD1 recruitment to outer membrane of 
mitochondria, or could affect the ubiquitin proteaseom pathway (352, 366). Indeed, 
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recent evidence indicate that SOD1 could be traslocated trough ER-Golgi network and 
chromogranins, a protein expressed in neurons, interneurons and astrocytes, could act 
as chaperone-like protein to promote misfolded SOD1 secretion  and it has been 
demonstrated that extracellular mutant SOD1 can induce motor neuron degeneration.  
Finally, it has been proposed that endoplasmic reticulum (ER) stress response 
might exert a critical role in the disease pathogenesis. The ER is the site of synthesis 
and folding of secretory and membrane bound proteins. The capacity of the ER to 
process proteins is limited and the accumulation of misfolded proteins may activate 
different ER stress pathways. In particular, several mutated SOD1 cause alteration in 
calcium homeostasis, redox stress and energy deprivation, all conditions that result in 
ER stress (367). 
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I.C.  Intracellular organelles in neuronal function: the 
endoplasmic reticulum and its functions 
The endoplasmic reticulum (ER) is an important cellular organelle, located in 
the cytoplasm of all eukaryotic cells. It is involved in several cellular functions, such 
as regulation of calcium homeostasis, secretion of different proteins, and biosynthesis 
of lipids. The ER is organized into a netlike labyrinth of branching tubles and flattened 
sacs extending throughout the cytosol. The tubules and sacs are all thought to 
interconnect, so that the ER membrane forms a continuous sheet enclosing a single 
internal space, named ER lumen. The ER membrane separates the ER lumen from the 
cytosol, and it mediates the selective transfer of molecules between these two 
compartments (368).  
The ER plays a key role during protein folding: indeed, the ER Ca2+-dependent 
molecular chaperons act to allow the correct folding of new proteins and so only the 
correct folded protein can be translocated from ER to other cellular compartments. The 
folding of proteins involves also PDI (protein disulphide isomerase), an enzyme that 
catalyzes the formation of disulphide bound among polypeptidic chains  (369). In this 
context, another important role of the ER is represented by post-translational 
modifications, such as glycosylation and lipidations, which are fundamental for the 
correct folding of the proteins. All the misfolded or unfolded proteins are exported in 
the cytosol and degraded trough the ubiquitin-proteasome system. The ER is involved 
also in lipids biosynthesis, and controls cholesterol and membrane lipids production. 
Finally, the ER regulates the signal transduction through the releases of Ca2+. 
Ca2+ is a universal second messenger controlling a wide variety of cellular 
reactions and adaptive responses (370). Ca2+ is the most versatile intracellular 
messenger discovered so far, since it is involved in the regulation of almost all known 
cellular functions and reactions. Ca2+ concentration differs in the different cellular 
compartments: for example, in the extracellular fluid Ca2+ concentration is about 1 
mM and represents about the 50% of total calcium; instead, in the cytosol, Ca2+ 
concentration is about 100 nM. This marked difference is due to the binding of Ca2+ 
to different cysolic molecules or to its presence in organelles. Indeed, Ca2+ ions are 
presented in two different forms: cytosolic free Ca2+ and Ca2+ bound to proteins. In 
order to cross membranes and reach the cytosol, calcium ions require being free. 
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The intracellular Ca2+ concentration is finely regulated by different mechanisms 
that control the passage of the ion trough plasma membranes and trough membranes 
of organelles, which act as intracellular store of Ca2+. The ER represents the main store 
of intracellular calcium. Indeed, in the ER lumen the highest intracellular free Ca2+ is 
found (about 500 µM) (371). Other organelles that act as calcium store are 
mitochondria, Golgi apparatus, secretory granules and lysosomes. Except ER and 
mitochondria, however, the rule of the other intracellular calcium stores is not yet 
known. Anyway, the homeostasis of intracellular calcium concentration involves 
several ionic pumps, named Ca2+-ATPases, which coupled ATP (adenosine 
triphosphate) hydrolysis to Ca2+ ions transport against concentration gradient. 
In particular, the ER has different ionic channels and Ca2+-ATPases in 
membrane that controls Ca2+ influx and efflux through the lumen. The ionic channels 
are channel-receptors that connect the lumen of the organelle to the cytosol. When 
Ca2+ interacts with specific receptors, the ionic channels are opened and allowed the 
release of Ca2+ from the stores. The ionic channels are divided in two classes: the IP3-
dependent (inositol-1,4,5-triphosphate) channels and the Ry-dependent (ryanodine, an 
alkaloid used to experimental aims) channels (372).  
The IP3 receptors (IP3R) are activated by IP3 production, resulting by 
phospholipase C (PLC) activity. PLC, indeed, catalyzes the hydrolysis of PIP2 
(phosphatidyl-inositol-4,5-bisphosphate) in IP3 and DAG (diacylglycerol). When 
released by the membrane, IP3 spreads in the cytosol and binds a specific receptor, 
permitting the release of Ca2+ from its intracellular stores. In this context, Ca2+ 
regulates channel activations: indeed, it is a positive regulator in presence of low Ca2+ 
concentration, and a negative regulator in presence of high Ca2+ concentration. This 
mechanism first potentiates the activation of channel-receptor and Ca2+ efflux; then, 
when cytosolic Ca2+ concentration is too high, the receptor is inactivated to allow the 
restore of intracellular Ca2+ concentration (fig. 12).  
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Figure 12. IP3 binds its receptor and induces Ca2+ release from ER. Ca2+ translocates into the 
cytosol also through the activation of voltage-dependent calcium channels located on the 
plasma membrane.     
 
 
The ryanodin receptors (RyR) exist in three isoforms, named RyRI, RyRII, and 
RyRIII, codified by different genes. The three isoforms differ for localization: indeed, 
RyRI is the isoform of muscles; RyRII is expressed in cardiac tissue and in CNS; 
finally, RyRIII is expressed ubiquitously. This channel is a cationic channel poorly 
selective, because it allows the passage of several divalent cations. The activation of 
RyR is concomitant to voltage-dependent calcium channels activation. These channels 
act as “voltage-sensors”, because, after depolarization, they undergo conformational 
change that is transmitted to RyRI. In this way, RyRI is activated and allowed Ca2+ 
flux (372). The other isoforms, RyRII and RyRIII, are activated by cytosolic Ca2+, 
through a particular mechanism named “calcium-induced calcium release” (CICR) 
(fig. 13). The endogenous regulator of RyR seems to be cADP-ribose (cyclic adenosine 
diphosphate-ribose). 
 
Figure 13. Molecular mechanism of CICR: Ca2+ released into the cytosol activates RyR, 
potentiating Ca2+ release.   
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When both the channels are opened, the Ca2+ in the ER diffuses into the cytosol, 
causing an increase of intracellular calcium concentration. In the ER, Ca2+ is bound to 
different proteins of the ER lumen, which have low affinity for the ion. A family of 
ATPases, named SERCA (sarcoplasmic-endoplasmic reticulum Ca2+-ATPases), 
finally, restores the ER calcium concentration, permitting the cross of two Ca2+ ions 
for each hydrolyzed ATP molecule. SERCA are different from other Ca2+-ATPases 
for their sensibility to tapsigargin (Tg), which is a specific SERCA inhibitor (372) (fig. 
14).    
 
 
 
Figure 14.  IP3R, RyR and SERCA control of calcium concentration in the ER. (Churchill, et 
al., 2002). 
 
 
I.C.1. Endoplamic reticulum stress 
 ER stress refers to a state in which the accumulation of misfolded proteins in 
the ER lumen exceeds the capacity for folding and degradation. Several stimuli and 
pathological events could determine ER stress. The main events responsible of ER 
stress include: 
- glucose deprivation that determine a failure in post-transductional 
modifications;  
- alteration in cellular redox regulation, causing hypoxia and increase of 
oxidant molecules and misfolded proteins;  
- alteration in calcium homeostasis in the ER; indeed, in absence of Ca2+, 
molecular chaperons are not activated, causing an increase of misfolded proteins; 
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- high fat diet; 
- viral infections that cause an increase of viral proteins in the ER, conducing 
to activation of apoptosis and other cell death mechanisms; 
- disease, especially neurodegenerative disease, characterized by nuclear 
inclusions that cause accumulation of unfolded proteins in the ER for reduction of 
proteasome activity.  
The main cellular defense to ER stress is represented by the unfolded protein 
response (UPR). UPR could have two consequences: adaptation to new conditions or 
apoptosis. The adaptive response is associated with the activation of several 
transcriptional pathways, resulting in the expression of genes able to increase ER 
ability to promote protein folding or able to induce the ER-assisted degradation 
(ERAD) (369). These mechanisms contribute to eliminate unfolded proteins in the ER. 
Thus, all correctly folded proteins are traslocated to the secretory pathway, while the 
unfolded proteins are retrotranlocated to the ubiquitin-proteasome system, activated 
by ERAD (373). Concomitantly, in the nucleus, in order to support the translation of 
mRNA coding for proteins involved in UPR, the translation of other mRNA are 
inhibited. In this way, the entry of new proteins in the ER is reduced.  
During UPR, several pathways associated with cellular stress are activated. 
These pathways involve MAPK, JNK (Jun N-terminal kinase), p38MAPK, and, 
sometimes, NF-B (nuclear factor-B) mediated signaling.  
When UPR fails, cells induce their death trough caspase-dependent and 
independent mechanisms. The caspase-dependent cell death is defined apoptosis; the 
caspase-independent cell death, instead, includes necrosis and autophagy, a particular 
catabolic mechanism associated with lysosomal degradation of macromolecules, 
organelles and other damaged cellular compartments. Usually, autophagy is a 
prosurvival mechanism, especially in nutrients deprivation and hypoxia. It could be 
activated also by ER stress or in all situations that induce non apoptotic cell death 
(369). 
Alterations of calcium homeostasis in the ER could induce UPR and modify 
cellular events, resulting in cell survival or cell death. For example, a great increase of 
Ca2+ concentration in the ER could induce apoptosis through the activation of BCL-2 
(B-cell lymphoma 2). BCL-2 belongs to a family of protein located in the membrane 
of ER that includes pro- and anti-apoptotic members. These proteins act at 
mitochondrial level, and most of them are involved during the ER stress, because are 
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able to maintain calcium homeostasis and control cell death induced by different death-
inducing substances, such as tunicamycin, brefeldin-A, tapsigargin, and other 
oxidative molecules (369).  
The anti-apoptotic proteins, such as BCL-2 and BCL-XL, cause a reduction of 
basal calcium levels in the ER; the pro-apoptotic proteins BAX (BCL-2 associated X 
protein) and BAK (BCL-2 antagonist/killer), instead, mediate the opposite effect, 
causing an increase of Ca2+ concentration in the ER. Many evidence, indeed, 
demonstrated that BAX-/- cells and BAK-/- cells are characterized by a low Ca2+ 
concentration. How the proteins of BCL-2 family act in regulating calcium 
concentration is unclear. It is hypothesized an involvement of IP3R that are modulated 
by BCL-2 and BCL-XL, independently on IP3 concentration: these two proteins permit 
the efflux of calcium to the ER. In particular, BCL-2 is an anti-apoptotic protein that 
inhibit only apoptosis induced by ER stress; indeed, it is unable to prevent apoptosis 
induced by all the other mitochondria-dependent mechanisms (369).  
The ER calcium concentration is regulated also by BI1 (BAX inhibitor 1), a 
transmembrane protein located in the ER that interacts with the pro-apoptotic members 
of BCL-2 family. Precisely, BI1 interacts with BAX and so blocks cell death induced 
by oxidative stress and by the overexpression of BAX. The protective action against 
ER stress mediated by BI1 are demonstrated in transgenic knockout BI1-/- mice, which 
have an increased sensitivity to kidney damage induced by tunicamycin and to 
neuronal cell death. Moreover, the proteins of BCL-2 family require BI1 in order to 
regulate basal calcium concentration in the ER; it is showed, indeed, that, in BI1-/- 
cells, BCL-XL alone is unable to reduce Ca
2+ concentration in the ER. Actually, it is 
yet unclear whether BI1 require IP3R for its function. Finally, in the ER, the pro-
apoptotic protein BAP31 (B-cell receptor-associated protein 31), by binding BCL-2 
and BCL-XL, activates apoptosis and induces an increase of ER calcium concentration 
(369).  
The alteration in the ER calcium concentration are important in regulating cell 
death: indeed, whether ER recognizes a low amount of free Ca2+, in stress conditions, 
the ER cannot induce Ca2+ release into the cytosol and, consequently, pro-apoptotic 
effectors are not activated.  
In the molecular mechanisms of cell death, ionic channels seem to be involved, 
as shown by mutations in the genes coding for ER Ca2+ channels. For example, in C. 
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elegans, it was demonstrated that mutations in IP3R or in RyR prevent neuronal cell 
death.  
Finally, calcium is involved also in ER stress-induced autophagy. In ER stress 
conditions, indeed, pro-autophagic proteins are activated; these proteins include  
PKC (protein kinase C), and CaMKK (calmodulin-dependent kinase kinase-) 
(369). Furthermore, high Ca2+ levels induce the activation of some Ca2+-dependent 
proteases, such as calpain, expressed in almost all tissues concomitant to their inhibitor 
calpastatin. In physiological condition, calpain mediates different cellular processes, 
such as turnover and removal of membrane receptors, enzyme activation, and mitosis 
(372). Marked levels of calcium induce the dissociation of calpain-calpastatin 
complex, resulting in irreversible activation of calpain. Instead, in ER stress condition, 
calpain induces apoptosis through the cleavage of BAX and BID, which are activated, 
BCL-2 and BCL-XL, which are inactivated, and several caspases, included caspase-
12.  
Finally, it is possible that alteration in calcium concentration could affect not 
only calcium release from ER, but also the transductional events that mediate UPR and 
that are important in the regulation of cell death (369).  
 
 
I.C.2.  The unfolded protein response 
The unfolded protein response (UPR) is the first defense against misfolded 
proteins accumulated in the ER. The activation of UPR involves several proteins that 
induce several transductional mechanisms: these proteins could induce an increase of 
ER chaperones, could block mRNA translation in order to prevent the entry of new 
proteins in the ER, and could accelerate retrograde export of proteins from the ER to 
the cytosol in order to induce ubiquitination and proteasome-dependent degradation.  
In the UPR, GRP78 (glucose-regulated protein 78 kDa), also named BiP 
(binding immunoglobulin protein), plays a key role. GRP78, in particular, is a 
molecular chaperone resident in the ER. In physiological conditions, GRP78 is 
associated with three transmembrane proteins of the ER, named IRE1, PERK, and 
ATF6. These three proteins are considered as “stress sensor” of the organelle, because 
their bound with GRP78 inhibit their activation. In ER stress conditions, misfolded 
proteins accumulated in the ER lumen, bind GRP78, resulting in the dissociation of 
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GRP78 bound to the three stress sensors. In this way, the three proteins are activated 
and UPR can start in order to attenuate ER stress (374).  
Precisely, the serine/threonine kinase PERK (PRKR-like ER kinase) is activated 
by oligomerization and autophosphorylation. When activated, PERK phosphorylates 
the initiation factor of the translation eIF2α (eukariotic initiation factor-2α), causing 
its inactivation. The inactivation of eIF2α determines the global repression of protein 
synthesis and so reduces the cargo of new proteins in the ER. Oligomerization and 
autophosphorylation induce also the activation of IRE1 (inositol-requiring kinase 1); 
IRE1, once activated, induce alternative splicing of the pre-mRNA coding for XBP1 
(X-box-binding protein 1), resulting in the production of XBP1-s (spliced X-box-
binding protein 1), a very stable transcriptional factor. XBP1-s migrates into the 
nucleus and activates the transcription of several genes involved in UPR and ERAD. 
Moreover, IRE1 and XBP1 promote cleavage and degradation of several mRNA 
coding for secretory proteins, causing a further reduction of proteins in the ER. Finally,   
ATF6 (activating transcription factor 6), after its dissociation to GRP78, translocates 
into the Golgi apparatus. Here, proteases cleave ATF6 on a juxtamembrane site, 
causing its release into the cytosol. Once in the cytosol, ATF6 can translocate into the 
nucleus, where activates the expression of some target genes, included GRP78, PDI, 
and EDM1 (ER degradation-enhancing α-mannosidase-like protein 1). Collectively, 
the activation of these genes causes an increased activity of molecular chaperons in 
the ER and allows misfolded proteins degradation (369) (fig. 15). 
 
 
Figure 15. During UPR, IRE1 (a), PERK (b), and ATF6 (c) activate different pathways in 
order to restore the ability of ER to promote the correct folding of the proteins (Hetz, et al., 
2013). 
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Thus, UPR, in the first phase of ER stress, tries to restore the normal functions 
of the ER and shows a protective rule. However, whether the stress conditions are not 
solved and the ER function is serious compromised, apoptosis is activated in order to 
eliminate damaged cells.   
Actually, it is known that almost three different molecular pathways are involved 
in the apoptotic process: the first pathway requires the activation of the gene coding 
for CHOP; the second one require caspase-12 activation; finally, the third one induces 
the expression of JNK kinase (375). While the activation of CHOP and caspase-12 are 
considered specific ER stress events, JNK pathway is activated in several type of 
cellular stress (376) (fig. 16).  
 
 
 
Figure 16. Pro-apoptotic transductional pathways activated by prolonged ER stress conditions 
(Van der Kallen C.J.H., et al., 2009).  
 
 
CHOP (C/EBP homologous protein), named also GADD153 (growth arrest and 
DNA damage inducible protein 153), is a transcription factor of 29 kDa expressed 
ubiquitously. In physiological condition, CHOP are expressed in the cytosol at very 
low levels; in ER stress condition, instead, the transcription of the gene coding for 
CHOP increases and the protein accumulates into the nucleus. It has been 
demonstrated that PERK/eIF2α pathway plays a key role for the activation of CHOP 
in ER stress conditions. Indeed, the phosphorylated eIF2α up-regulates the 
transcription factor ATF4 (activating transcription factor 4), which induces an increase 
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of CHOP (374). Moreover, it has been demonstrated that also ATF6 induces also 
CHOP transcription; finally, IRE1/ASK1/p38MAPK can increase CHOP activity at 
post-transcriptional level, after the phosphorylation mediated by p38MAPK. Another 
CHOP activator is ATF2, a transcription factor induced by hypoxia and required for 
CHOP expression in absence of aminoacids. The over-expression of CHOP causes cell 
cycle arrest and induces apoptosis activation; several studies, indeed, demonstrate that 
CHOP can activate apoptosis by increasing BIM expression and by inhibiting BCL-2. 
In addition, CHOP promotes the expression of several genes coding for ER proteins, 
increasing the amount of proteins in the organelle and exacerbating oxidative stress 
(368). In ER stress conditions, the overexpression of GRP78 determines a reduction 
of CHOP that affects negatively apoptosis. Moreover, in transgenic CHOP-/- mice, ER 
stress-induced apoptosis was reduced. These results confirm that CHOP plays a key 
role in the activation of apoptosis during ER stress (375).   
In mice, the second pathway involved in apoptosis activation requires caspase-
12 activation. The caspase-12 is a cysteine-pretease belong to the caspases family that 
acts as pro-apoptotic proteins. In particular, capsapse-12 is activated in ER stress 
condition after IREI1 activation (369), and, usually, it is not involved in cell death 
induced by ER-independent stimuli (377). In physiological condition, caspase-12 is 
bound to ER membrane as inactive enzyme associated with GRP78. In ER stress 
condition, instead, the Ca2+ mobility induces calpain activaton, determining cleavage 
of capsase-12 and its activation. Caspase-7 can activate pro-caspase-12 too, by 
traslocating from cytosol to ER (378). Once activated, caspase-12 induces the 
activation of downstream caspase-9 and caspase-3, DNA fragmentation, and promotes 
apoptosis (374, 376). In humans, polymorphism analysis reveal that caspase-12 is not 
fundamental for apoptosis activation; indeed, in most of men, the gene of caspase-12 
is inactivated by nonsense mutations (369). However, these men can activate 
apoptosis, suggesting that caspase-12 is substituted by different caspases activated by 
ER stress. Moreover, several studies demonstrated that rat caspase-12 has a high 
sequence homology (about 48% of identity) with human caspase-4, which is involved 
in ER stress-induced apoptosis (377), suggesting that in humans caspase-4 can 
substitute caspase-12. 
Finally, JNK pathway is involved in cell death mechanisms, but this pathway is 
not specific for ER stress. Anyway, in ER stress condition, JNK, activated by the 
bound between IRE1 and adapter protein TRAF2 (TNF receptor-associated factor 2), 
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phosphorylates the pro-apoptotic protein BIM and inhibits the anti-apoptotic protein 
BCL-2, inducing apoptosis.  
 
 
I.C.3. ER stress and neurodegenerative diseases 
The ER is the first compartment of the secretory pathway associated with 
protein synthesis, post-translational folding, and modification. Thus, all situation that 
determine accumulation of misfolded protein in the ER lumen cause ER stress.  
ER stress is a pariticular condition that could be involved in the pathogenesis 
of several neurodegenative and non-neurodegenerative disease or could be 
conseguence of pathological processes.  
Thus, ER stress plays a key role in neurodegenerative disease characterized by 
misfolded protein accumulation or protein inclusions, such as Amyotrophic Lateral 
Sclerosis (ALS), Alzheimer’s disease (AD), juvenile Parkinson’s disease (PD), 
Huntington’s disease (HD), and cerebral ischemia.  
In addition, many evidence indicates that ER stress plays a key role also in 
several non-neurodegenerative diseases, such as myocardial ischemia, cardiac 
hypertrophy, cardiac failure, arteriosclerosis, diabetes, some cancers and autoimmune 
disorders (369). All these diseases is caused by specific alterations, but, in each one, 
UPR activation and apoptosis are observed (table 3).  
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Table 3. Neurodegenerative and non-neurodegenerative diseases associated with ER stress. 
 
 
 
 
 
Disease Neurodegeneration 
ER stress induced 
mechanisms 
Pharmacological 
targets  
Alzheimer’s 
Disease (AD) 
Yes 
 The exact mechanisms of ER stress 
are yet unknown; anyway, in the 
nervous system, the expressions of 
proteins involved in the UPR are 
increased. 
 Mutated presenilin-1 induces ER 
stress and affects UPR, reducing 
IRE1, PERK, and ATF6 activity 
 
Presenilin, 
PERK-eIF2
 
Parkinson’s 
Disease (PD) 
Yes 
 In physiological conditions, parkin 
prevents cell death induced by ER 
stress.  
 ER stress induce an increase of 
parkin. 
 Mutations in parkin are associated 
with PD.  
Parkin, 
-sinuclein, and 
other proteins  
Amyotrophic 
lateral 
sclerosis (ALS)  
Yes 
 
 Mutated SOD1 affect ERAD and 
activates ASK1.  
 
SOD, ASK1 
Huntington’s 
Disease (HD) 
Yes  Polyglutamine expansions induce 
UPR and inhibit proteasome activity. 
Huntingtin 
Cerebral 
ischemia  
Yes 
 Ischemia induces, in neurons, ER 
stress, UPR, and apoptosis through 
CHOP and ASK1 activation  
PERK- eIF2, ASK1 
Cardiac 
diseases  
No 
 ER stress induced cardiomyocytes 
degeneration.  
 Myocardial infarction (heart attack) 
induces an increase of UPR markers.  
ASK1 
Atherosclerosis No  Oxidated lipids and homocystein 
induce ER stress in vascular cells 
IRE1 pathway 
Type 1 
diabetes  
No 
 Alteration in PERK pathway causes 
type 1 diabetes (Wolcott-Rallison 
syndrome). 
PERK-eIF2
Type 2 
diabetes  
No 
 Obesity, often associated with type 2 
diabetes, induces ER stress dell’ER 
and promote insulin-resistance. 
XBP1, JNK 
Cancer No 
 The increase of proteins involved in 
UPR in cancer cells has a protective 
effect.  
GRP78, XBP1, 
PERK 
Autoimmune 
disorders  
No 
 The great amoun of protein in the ER 
could promote the production of 
autoantigens. 
 GRP78 seems to be an autoantigen. 
GRP78, HLA-B27, 
and other proteins  
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I.C.3.1 Amyotrophic Lateral Sclerosis 
ER stress seems to be involved in ALS, a disease characterize by several 
protein inclusions. It is hypothesized, indeed, that protein aggregates could exhaust 
proteasome activity, resulting in a secondary accumulation of misfolded proteins in 
the ER. In particular, Turner and Atkin, in 2006, proposed an integration of ER stress, 
UPR and Golgi apparatus (GA) dysfunctions in mutant SOD1-induced neurotoxicity 
in ALS.  
In this model, secretory pathway is maintained in presence of wt SOD1, which 
is exported to act in the extracellular space. In ALS, mutated SOD1 interacts with the 
GA, causing its fragmentation by an unclear mechanism. GA fragmentation, then, 
results in increased retrograde flow of Golgi-associated membranes and proteins, 
including mutated SOD1, into the ER. In this way, misfolded SOD1 and impaired 
retrotranslocation due to proteasomal inhibition may induce aggregation and binding 
to ER-resident chaperones, such as GRP78. The activation of GRP78, finally, results 
in UPR and apoptosis. Thus, these pathways may contribute to motor neuron 
degeneration and experimental manipulation of UPR and ERAD components could 
help to better understand ER stress role in ALS (374) (fig. 17).  
On the other hand, different evidence indicated that mutated SOD1 is unable 
to block proteasome activity, but is able to bind derlin-1, which is a component of 
ERAD. This interaction induces ER stress, because it interferes with ERAD and 
contributes to motor neurons death (379).  
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Figure 17. A proposed model for mutant SOD1-mediated disruption of the ER-Golgi system 
in Fals (Turner B.J., Atkin J.D., 2006) 
 
 
I.C.3.2. Cerebral ischemia  
Ischemic stroke is the third cause of death and a major cause of long-lasting 
disability in industrially developed countries, only surpassed by heart disease and 
cancer. It is a pathological condition resulting from occlusion or hemorrhage of blood 
vessels supplying oxygen and essential nutrients to the brain. 
 In all cases, stroke ultimately induces death and/or dysfunction of brain cells, 
as well as neurological impairments that reflect the location and size of the ischemic 
brain area. Even though a large number of compounds have been proven to reduce 
ischemic injury in experimental animal models, clinical trials have reported 
disappointing results because of toxic side effects. Actually, the only FDA (US Food 
and Drug Administration) approved treatment is to provide tissue plasminogen 
activator (tPA) to re-open occluded blood vessels. However, due to a narrow time-
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window of 4,5 hours after the stroke onset (380), this treatment is only appropriate for 
every small number of patients. Thus, research on the discovery of novel mechanisms 
and the development of new drugs for treating cerebral ischemia are imperative. 
Cerebral ischemic event triggers a set of complex pathological mechanisms, 
eventually leading to death and/or dysfunction of brain cells, including excitotoxicity, 
oxidative and nitrosative stress, inflammation, and apoptosis. Each of these 
mechanisms have a different timing and cause injury to neurons, glia and endothelial 
cells (fig. 18). 
  
 
 
 
Figure 18. Damaging cascades of events after cerebral ischemia (Dirnagl, et al., 1999). 
 
 
Within the core of the ischemic area, where blood flow is most severely 
restricted, excitotoxic and necrotic cell death occurs within minutes. Instead, in the 
periphery of the ischemic area, where collateral blood flow can buffer the full effects 
of the stroke, the degree of ischemia and the timing of reperfusion determine the 
outcome for individual cells. In this ischemic penumbra cell death occurs less rapidly 
via mechanisms such as apoptosis and inflammation (381, 382). 
Ischemia determines energy depletion. Thus, after ischemic damage, important 
ion pumps found on the plasma membrane of neurons, such as Na+/K+-ATPase and 
CA2+-ATPase, cannot longer function. Thus, in affected neurons, depolarization, 
release of potassium into the extracellular space and entry of sodium into the cells 
occur (383). Consequently, calcium dependent proteases, lipases and DNases are 
activated, eventually leading to catabolism and death of many cells in the ischemic 
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core. In addition, membrane depolarization results in neurotransmitter release, most 
prominently the release of the excitatory neurotransmitter glutamate, which plays a 
central role in the pathology of cerebral ischemia (384). Increase in synaptic glutamate 
concentration overactivates its receptors, N-methyl-D-aspartate (NMDA) and α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and metabotropic 
glutamate (mGlu) receptors, which in return cause further membrane depolarization 
and greater calcium influx, exacerbating excitotoxicity (385- 387). 
Furthermore, unlike other organs, brain is too vulnerable to reactive oxygen 
species (ROS), because neurons have low levels of endogenous antioxidants (388). 
Thus, in presence of high levels of intracellular calcium, sodium and ADP, 
mitochondria produce deleterious high levels of ROS, and consequently, oxygen 
radicals cause the destruction of cellular macromolecules and participate in signaling 
mechanisms that result in apoptotic cell death (389). Moreover, there is an increased 
production of superoxide, NO and peroxynitrate, following reperfusion. These free 
radicals, finally, determine a second oxidative and nitrosative stress, increasing the 
risk of brain hemorrhage and edema. 
Ischemic injury preferentially induces cell death trough an apoptotic-like 
mechanism rather than necrosis. Because the ischemic penumbra sustains milder 
injury and preserves ATP, apoptosis predominates in this region (382). In ischemia-
induced neurons cell death, apoptosis could be activated by the intrinsic or the extrinsic 
pathways. Indeed, oxygen free radicals, death receptor ligation, DNA damage and 
protease activation induce cytochrome c release from the outer mitochondrial 
membrane, an event which is promoted or prevented by Bcl-2 family of proteins, and 
initiates the intrinsic apoptotic cascade. Instead, extrinsic apoptosis pathway could be 
activated by inflammatory signals, such as TNF family of ligands (390). Eventually, 
downstream effector caspases are activated targeting the substrates that dismantle the 
cell by cleaving homeostatic, cytoskeletal, repair, metabolic and cell signaling proteins 
(391). 
Finally, inflammation contributes to cerebral ischemic injury. Effects of 
individual components of the inflammatory cascade, however, can be beneficial 
depending on the stage of tissue injury, the magnitude of the response and whether the 
inflammatory components activate neuroprotective pathways (392-394). After stroke, 
immune cells can gain access to brain parenchymal tissue. Infiltration of bone marrow-
derived cells into the ischemic brain persists for weeks following stroke, and while the 
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initial infiltration leads to worsening of tissue damage and exacerbation of 
neurological deficits, subsequent aspects of the infiltration such as the phagocytosis of 
debris and the release of cytokines that promote glial scar formation could be crucial 
for effective wound healing. On the other hand, numerous cytokines and chemokines 
are produced by activated endothelial cells, microglia, neurons, platelets, leukocytes, 
and fibroblasts and contribute to ischemic brain injury (395, 396). In particular, IL-1, 
TNF-α and toll-like receptors (TLRs) are important inflammatory factors with 
detrimental effects for stroke outcome (396-309). In contrast, TGF-β was reported to 
play a neuroprotective role in the pathogenesis of stroke (400). 
In ischemic neurons, the depletion of calcium ions from the endoplasmic 
reticulum (ER) has been suggested as an initial signal for ER dysfunction. Many 
studies indicate that a strong release of calcium ions from ER, due to ion channels or 
Ca2+ transport systems, or through the release of Ca2+ ions from intracellular stores, is 
associated with damage to cells, including damage to neurons after ischemia.  
In particular, stimuli such as ischemia, hypoxia, hypertension and hypoglycemia, 
might trigger the accumulation of unfolded protein in the ER lumen, leading to UPR, 
which involves expansion of ER membranes, accelerated degradation of unfolded 
proteins, increased translation of folding chaperones, and inhibition of other protein 
synthesis (401, 402). Then, reperfusion of tissues determines oxidative stress 
associated with NO and ROS production, causing alteration of redox reactions, and 
misfolding of proteins, both situations that exacerbate ER stress (fig. 19). 
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Figure 19. Cerebral ischemia exacerbates ER stress, determining UPR activation and cell 
death, usually apoptosis.  
 
 
In mice, for example, ischemia and reperfusion damage activate PERK-eIF2α 
pathway, resulting in CHOP activation. However, in transgenic CHOP-/- mice, the loss 
of tissues induced by ischemia are less evident, suggesting that CHOP has a casual 
role in neuronal cell death induced by ischemic-mediated ER stress. In addition, NO, 
responsible to tissue damage after ischemia, promotes CHOP expression in primary 
cultures of neurons and knockout mice for iNOS (inducible nitric oxide synthase, also 
named NOS2), show a minor activation of CHOP and are less sensitive to cerebral 
ischemia.  
However, ER-stress induced apoptosis plays an important role in the 
pathophysiology of cerebral ischemia and it is possible that the timing of events for 
ER stress signaling regulation is important for the balance of life and death, such that 
ER stress is initially protective, aiming to restore ER homeostasis, whereas prolonged 
periods of ER stress can be deleterious and damaging. Nevertheless, modulation of ER 
stress exerts a remarkable protective effect on the ischemic brain and thus may be used 
as a therapeutic target for ischemic stroke (376). 
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Aim of the study 
 
Many data demonstrate that SOD1 is secreted in many cellular lines, as human 
neuroblastoma SK-N-BE cells (403) and rat adenohypophysis GH3 cells (326), in 
basal condition and after depolarization mediated by high K+ concentration.  
Moreover, many evidence also shows that SOD1 secretion is compromise in 
ALS; indeed, mutant SOD1 is not secreted, but accumulates in motor neurons (366), 
best of all in the endoplasmatic reticulum and in Golgi apparatus (352). SOD1 
aggregates cause mitochondrial dysfunction, ER stress and motor neuron 
degeneration. Thus, it seems that mutation in SOD1 are associated with a gain of toxic 
function rather than a loss of function. 
In addition, SOD1 administration in SOD1G93A transgenic mice could modify 
motor symptom of disease (366), and, at last, recent evidence showed that SOD1 is 
released by microglial cells and protect against the toxicity mediated by 6-hydroxy-
dopamine (6OHDA) (404). However, the molecular mechanism of this 
neuroprotection is yet unknown.    
Furthermore, SOD1 could activate the transductional pathway phospholipase 
C (PLC)/ protein kinase C (PKC), resulting in an increase of intracellular Ca2+ 
concentration. This activation is independent on dismutase activity, because also 
ApoSOD, the enzyme without catalytic activity, could activate PLC/PKC pathway, 
while mimetic drugs, as MnTMPyP, have not the same effect (325). Moreover, SOD1 
could activate also downstream kinases of PLC/PKC pathway, as p-ERK1/2 and p-
Akt (327), and drugs, as the insulin-like growth factor 1 (IGF-1), partially prevent 
motor neuron loss in SOD1G93A transgenic mice through ERK1/2 activation (405).  
Finally, it is known that endoplasmic reticulum stress plays a key role in 
neurodegenerative disorders, such as Alzheimer’s disease or Parkinson’s disease. In 
the last years, it has been demonstrated that ER stress and the unfolded protein 
response (UPR) are involved in the pathogenesis of mutant SOD1 linked-ALS (374).  
Thus, the main aim of this study was to analyze the eventual neuroprotective 
effects exerted by SOD1 and the molecular mechanism underlies this neuroprotection.  
Because SOD1 is released in many cellular lines, firstly SOD1 release in motor 
neurons has been studied, together with its ability to induce the activation of p-ERK1/2 
and p-Akt prosurvival pathways.    
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Then, the eventual neuroprotective effects exerted by SOD1 in two different 
neurotoxic models have been studied. In particular, motor neurons will exposed to L-
BMAA, a neurotoxin associated with ALS/PDC, in order to obtain an in vitro model 
mimicking ALS. Moreover, motor neurons will also exposed to chemical hypoxia, in 
order to reproduce in vitro a Ca2+- and ROS-dependent model of neurodegeneration.  
Because SOD1 is an antioxidant enzyme able to induce ERK1/2 and Akt 
phosphorylation, in the second part of our study, the ability of SOD1 to exert 
neuroprotective effects independently from its catalytic activity will be tested together 
with its transdctional actions. To this aim, the effects exerted by SOD1 will compared 
to the effects exerted by two different drugs: ApoSOD, the enzyme lacking catalytic 
activity, and MnTMPyP pentachloride, a SOD mimetic drug. 
In addition, because more than 150 mutations in the gene coding for SOD1 
associated with ALS are described, the effects exerted by SOD1 will be compared to 
those exerted by two different recombinant proteins: the recombinant wild type SOD1, 
and the recombinant SOD1G93A. Indeed, the second recombinant protein shows one of 
the best-characterized mutations associated with ALS.  
Finally, in order to better characterize the neuroprotection mediated by SOD1, 
the ability of SOD1 to prevent ER stress in motor neurons exposed to L-BMAA or to 
chemical hypoxia will be tested .
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III.1. Reagents 
Media and sera for cell culture were purchased from Invitrogen (Milan, Italy); 
antibiotics for cell culture were from Sigma-Aldrich (St. Louis, MO, USA).  
Rabbit polyclonal antibody against SOD1, mouse monoclonal antibody against 
p-ERK1/2, rabbit polyclonal antibody against ERK1/2, and mouse monoclonal 
antibody against neuronal nitric oxide synthase (n-NOS) were from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA, USA). Mouse monoclonal p-Akt antibody, 
mouse monoclonal caspase-3 antibody, mouse monoclonal caspase-12 antibody, 
mouse monoclonal CHOP antibody, and rabbit polyclonal GRP78 antibody were from 
Cell Signaling Technology Inc. (Danvers, MA, USA). Mouse monoclonal SMI-32 
antibody was from Covance-Signet (CA, USA). Mouse monoclonal antibody against 
the axonal growth-associated protein-43 (GAP-43), and mouse monoclonal β-tubulin 
antibody was from Sigma-Aldrich (St. Louis, MO, USA).  
Western blotting, ECL reagents, and chemicals were from GE Healthcare 
(Milan, Italy).  
The inactive mutant HA-Aktk179M (Akt D-) plasmids was donated by P. 
Formisano (University of Naples “Federico II”, Naples, Italy), as described by Eves et 
al., 1998 and Trencia et al., 2003. siRNA-MEK1 and siRNA-CONTROL were 
purchased from Dharmacon RNA Technologies (Thema Ricerca, Italy).  
SOD1, retinoic acid, L-BMAA, oligomycin, 2-deoxy-glucose, EGTA 
(ethylene glycol tetraacetic acid), ω-conotoxin, L-nimodipin, H2O2, LY294002, 
PD98059, fluorescein, propidium iodure, and all other reagents were from Sigma 
(Milan, Italy). 2′,7′-dichlorofluorescin diacetate (DCFH-DA) was purchased from 
Calbiochem (San Diego, CA, USA). MnTMPyP pentachloride was purchased from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). 1-[2-(5-Carboxyoxazol-2-yl)-
6-aminobenzofuran-5-oxy]-2-(21-amino-51-methylphenoxy)-ethane-N,N,N1,N1-
tetra-acetic acid penta-acetoxymethyl ester (fura-2AM) was from Molecular Probes 
(Invitrogen Italia, Milan, Italy).  
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III.2. Cell culture 
Mouse motor neuronal NSC-34 cells are a hybrid mouse-mouse NSC cell line 
(neuroblastoma and spinal cord) that resembles motor neurons; indeed, these cells 
display a multipolar neuron-like phenotype, express choline acetyltransferase and 
neuroﬁlament triplet proteins, and generate action potentials (243). Actually, these 
cells are considered the best stable motor neuronal cell line model system available. 
NSC-34 cells were grown in monolayer in Dulbecco’s Modified Eagles 
Medium (DMEM) containing 4.5 g/L glucose, supplemented with 10% FBS (fetal 
bovine serum), 2 mM L-glutamine, 100 IU/mL penicillin and 100 μg/mL 
streptomycin. The cells were kept in a 5% CO2 and 95% air atmosphere at 37° C. 
Before each experiment, NSC-34 cells were differentiated in 10 µM retinoic 
acid for 48 h.  
NSC-34 cells were stably transfected with pTet-ON plasmid, coding for the 
reverse tetracycline-controlled transactivator, to obtain the line designed NSC-34-
ON7, which displays a very low level of basal expression and high inducibility. NSC-
34-ON7 was used to construct inducible cell lines expressing the cDNAs encoding 
human wild type (wt) SOD1 or the human SOD1G93A inserted in the pTRE2 plasmids 
(406). These cells were grown in DMEM supplemented with 10% tetracycline-free 
FBS, 2 mM L-glutamine, 100 μg/mL hygromicin B and 100 μg/mL geneticin in an 
atmosphere of 5% CO2 and 95 % air atmosphere at 37° C. 
Before each experiment, the induction of human wt SOD1 or SOD1G93A 
expression was obtained by adding 1 µg⁄mL doxycycline to the culture medium for 48 
h. Moreover, NSC-34 SOD1G93A motor neurons were, at the same time, differentiated 
in 10 µM retinoic acid for 48 h. 
 
 
III.3. Motor neuron-enriched cultures 
Motor neuron-enriched cultures were prepared from spinal cord of 12-14-days-
old C57BL/6 wild type mouse embryos. Briefly, mice were anesthetized and then 
sacrificed by cervical dislocation euthanasia, and spinal cords were isolated from each 
embryo.  
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Dissection and dissociation were performed in MgSO4 phosphate-buffered 
saline (PBS) containing penicillin and streptomycin. Tissues were dissociated by 
trituration and centrifuged for 2 min at 1000 rpm. Then, tissues were incubated with 
trypsin for 20 min in a 37° C water bath, agitating. After that, tissues were treated with 
MgSO4-PBS containing penicillin and streptomycin, DNAse and trypsin. After a 
centrifugation for 2 min at 1000 rpm, tissues were incubated again with DNAse and 
trypsin in MgSO4-PBS containing penicillin and streptomycin and then cells were 
separated by density gradient. Finally, cells were centrifuged for 10 min at 1000 rpm 
and plated at 8 x 104 in glass coverslip pre-coated with poly-D-lysine (20 µg/mL) in 
Neuron Basal Medium (Gibco, Life Technologies), supplemented with B27 and 2 mM 
L-glutamine. 
Motor neurons were cultured at 37° C in a humidified 5% CO2 atmosphere and 
used after 12 days of cultures. 
All the experiments on primary motor neurons were performed according to 
the procedures described in experimental protocols approved by the Ethical 
Committee of the ‘Federico II’ University of Naples. 
 
 
III.4. Immunocytochemistry and confocal image 
Mouse monoclonal SMI-32 antibody (Covance-Signet, CA, USA) was used for 
immunocytochemical experiments, useful to characterize differentiated NSC-34 motor 
neurons and primary motor neurons.  
NSC-34 cells were differentiated in 10 µM retinoic acid for 48 h; primary 
motor neurons, instead, were cultured on glass coverslips for 12 days. Then, the cells 
were rinsed twice in cold 0.01 M saline phosphate buffer at pH 7.4 (PBS) and fixed in 
4% (w/v) paraformaldehyde (Sigma, Milan, Italy) for 20 min at room temperature 
(RT). Following three washes in PBS, cells were blocked with 3% (w/v) bovine serum 
albumin (BSA) and 0.05% Tryton-X (Biorad, Milan, Italy) for 1 h at room temperature 
(RT). The coverslip were then incubated with the primary antibody anti-SMI-32 
(1:1000 diluition) at 4°C overnight. Following three washes in PBS, the coverslips 
were incubated in the dark with the secondary antibody, Alexa-fluor 488 anti-mouse 
IgG (Molecular Probes, Eugene, OR; diluition 1:200) for 1 h at RT. After the final 
wash, the coverslips and the cells were mounted with Vectashield (Vector Labs, 
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Burlingame, CA) and analyzed with a Nikon Eclipse 400 upright microscope (Nikon 
Instruments, Florence, Italy), equipped with a CCD digital camera (Coolsnap-Pro, 
Media Cybernetics, Silver Springs, MD, USA) and Image Pro-Plus software (Media 
Cybernetics, Silver Springs, MD, USA).  
 
 
III.5. [Ca2+]i measurements  
[Ca2+]i was measured by single cell computer-assisted video-imaging (407) 
Briefly, NSC-34 motor neurons grown on glass coverslips were loaded with 6 µM 
Fura-2 acetoxymethyl ester (Fura-2/AM) for 1 h at RT in normal Krebs solution 
containing the following (in mM): 5.5 KCl, 160 NaCl, 1.2 MgCl2, 1.5 CaCl2, 10 
glucose, and 10 Hepes–NaOH, pH 7.4. At the end of the Fura-2/AM loading period, 
the coverslips were placed into a perfusion chamber (Medical System, Co. Greenvale, 
NY, USA) mounted onto a Zeiss Axiovert 200 microscope (Carl Zeiss, Germany) 
equipped with a FLUAR 40X oil objective lens. The experiments were carried out with 
a digital imaging system composed of MicroMax 512BFT cooled CCD camera 
(Princeton Instruments, Trenton, NJ, USA), LAMBDA 10-2 filter wheeler (Sutter 
Instruments, Novato, CA, USA), and Meta-Morph/MetaFluor Imaging System 
software (Universal Imaging,West Chester, PA, USA). After loading, cells were 
alternatively illuminated at wavelengths of 340 and 380 nm by a Xenon lamp. The 
emitted light was passed through a 512 nm barrier filter. Fura-2 fluorescence 
intensitywas measured every 3’’. All the results are presented as cytosolic Ca2+ 
concentration.  Assuming that the KD for FURA-2 was 224 nM, the equation of 
Grynkiewicz et al. (1985) (408), whose parameters were determined for individual 
cells as described by Urbanczyk et al. (2006) (409) was used for calibration. 
 
 
III.6. NSC-34 motor neurons depolarization  
After differentiation in 10 µM retinoic acid for 48 h, NSC-34 motor neurons 
were exposed to a Normal Krebs solution, containing, in mM, 5.5 KCl, 100 NaCl, 1.2 
MgCl2, 1.5 CaCl2, 10 glucose and 10 Hepes-KOH pH 7.4.  or to a Krebs solution at 
different K+ concentration (9 or 55 mM) for 5, 10 e 30 min. 
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The depolarization mediated by 55 mM K+ was also evaluated in presence of 
50 nM ω-conotoxin (inhibitor of neuronal (N) calcium channels), 1 µM L-nimodipine 
(inhibitor of long-lasting (L) calcium channels) or 1 mM EGTA (extracellular calcium 
chelator) for 10 min. 
At the end, supernatants and cells were collected separately and analyzed by 
Western blotting.  
 
 
III.7. Cell transfection and RNA interference 
Transfection of NSC-34 motor neurons was carried out using HyPerFect 
Transfection Reagent. Small interfering RNA (siRNA) or plasmids were added to 
HyPerFect Transfection Reagent for 15 min at room temperature, and then the mixture 
was added to cells plated on 60-mm-diameter plastic dish or on multiple well cluster 
plate (6 wells) in Optimem medium. After 5 h of incubation, the medium was replaced 
with fresh medium.  
For the silencing, 10 µM siRNA against MEK1 (mitogen-activated protein 
kinase kinase 1) was used (siMEK1); for the transfection with the dominant negative 
form of Akt (Akt D-), 2 µg/µL plasmid was used.  
 
 
III.8. L-BMAA treatment 
NSC-34 motor neurons were plated in multiple well cluster plate (6 wells; 
density: 5x105 cells) and differentiated, as previous described. At the end of 
differentiation, the culture medium was replaced with DMEM supplemented with 0.2 
% FBS, 2 mM L-glutamine, 100 IU/mL penicillin and 100 μg/mL streptomycin, and 
the cells were treated with 300 µM L-β-methylaminoalanine (L-BMAA) for 48 h in 
absence or in presence of 400 ng/mL SOD1 (pre-incubated for 10 min).  
NSC-34 motor neurons were also pre-incubated with 400 ng/mL ApoSOD or 
with 400 ng/mL MnTMPyP pentachloride for 10 min and the exposed to 300 µM L-
BMAA for 48 h.   
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At the end of all pharmacological (50 µM PD98059 for 10 min and 10 µM 
LY294002 for 30 min) and molecular (10 µM siMEK1 and 2 µg/µL Akt D-) 
treatments, cell viability was measured by MTT assay.  
 
 
III.9. Chemical Hypoxia 
Chemical hypoxia was reproduced by adding to the cells, for 45 to 180 min, 5 
µg/ml oligomycin (a oxidative phosphorylation inhibitor) plus 2 mM 2-deoxyglucose 
(a glycolis inhibitor) in glucose-free medium composed of 145 mM NaCl, 5.5 mM 
KCl, 1.2 mM MgCl2, 1.5 mM CaCl2, and 10 HEPES, pH 7.4, as described previously 
(410). Control cells were exposed for the same amount of time to Normal Krebs 
solution composed of 145 mM NaCl, 5.5 mM KCl, 1.2 mM MgCl2, 1.5 mM CaCl2, 
10 mM glucose, and 10 mM HEPES, pH 7.4. 
NSC-34 motor neurons were pre-incubated with 400 ng/mL SOD1, 400 ng/mL 
ApoSOD or with 400 ng/mL MnTMPyP pentachloride for 10 min and then exposed 
to chemical hypoxia for 45 min.  
At the end of all pharmacological (50 µM PD98059 for 10 min and 10 µM 
LY294002 for 30 min) and molecular (10 µM siMEK1 and 2 µg/µL Akt D-) 
treatments, cell viability was measured by MTT assay. 
 
 
III.10. Western blotting analysis 
After treatments, cells and supernatants were washed in phosphate-buffered 
saline (PBS) and lysed by gentle scraping in ice-cold lysis buffer containing  20 mM 
Tris-HCl (pH 7.5), 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1% NONIDET 
P-40, 1 Mm Na3VO4, 0.1% aprotinin, 0.7 mg/mL pepstatin and 1 µg/mL leupeptin. 
Protein concentration was determined by Bradford method (411).  
For SOD1 expression, proteins (50 µg) or supernatants (60 µL) were first 
separated on 12% SDS-polyacrylamide gels and transferred onto Hybond ECL 
nitrocellulose membranes (Amersham). Membranes were blocked with 5 % nonfat dry 
milk in 0.1 % Tween 20 (Sigma Aldrich) (2 mM Tris-HCl and 50 mM NaCl, pH 7.5) 
for 2 h at room temperature,  and then they were incubated overnight at 4° C in the 
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blocking buffer with the 1:1000 polyclonal antibody against SOD1 (Santa Cruz 
Biotecnology, Inc.).  
For GAP-43, nNOS, p-ERK1/2, p-Akt, GRP78, CHOP, caspase-3 and caspase-
12 expression, protein (50 µg) were separated on 10% SDS-polyacrylamide gels and 
transferred onto Hybond ECL nitrocellulose membranes (Amersham). Membranes 
were blocked with 5 % nonfat dry milk in 0.1 % Tween 20 (Sigma Aldrich) (2 mM 
Tris-HCl and 50 mM NaCl, pH 7.5) for 2 h at room temperature, and then they were 
incubated overnight at 4° C in the blocking buffer containing either: 
 monoclonal antibody (1:1000) against GAP-43 (Sigma-Aldrich (St. Louis, 
MO, USA); 
 monoclonal antibody (1:1000) against nNOS (Santa Cruz Biotecnology, Inc.); 
 monoclonal antibody (1:1000) against p-ERK1/2 (Santa Cruz Biotecnology, 
Inc.); 
 monoclonal antibody (1:1000) against p-Akt (Cell Signaling Technology Inc., 
Danvers, MA); 
 rabbit polyclonal (1:1000) against GRP78 (Cell Signaling Technology Inc., 
Danvers, MA); 
 monoclonal antibody (1:1000) against CHOP (Cell Signaling Technology Inc., 
Danvers, MA); 
All membranes were also incubated in the blocking buffer with the 1:1000 
monoclonal antibody against β-tubulin (Sigma-Aldrich). 
Finally, after the incubation with primary antibodies, membranes were washed 
with 0.1% Tween 20, followed by incubation with secondary antibodies for 1 h at room 
temperature. Immunoreactive bands were detected with the ECL reagent (Amersham). 
The optical density of the bands (normalized to β-tubulin) was determined by Chemi-
Doc Imaging System (Bio-Rad, Hercules, CA). 
 
 
III.11. Determination of cell viability 
III.11.1. MTT assay 
Cell viability was evaluated by the MTT assay (3[4,5-dimethylthiazol-2-yl]-
2,5-diphenyl-tetrazolium bromide), which measures mitochondrial activity. In this 
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test, the dye MTT is metabolized by viable mitochondria to a colored product than can 
be detected using a spectrophotometer at a wavelength of 540 nm. 
After toxic treatment, 1 mL MTT were added to each well for 1 h at 37° C; 
then, 1 mL of dymethil sulfoxide (DMSO) was added for complete solubilisation of 
the purple formazan crystal and the absorbance was measured at 540 nm. Data 
obtained were expressed as a percentage of cell viability of control cultures.  
 
III.11.2. Cell death 
Cell death was evaluated by measuring the ratio between dead and living cells. 
To quantify cell death after the experimental procedures, primary motor neurons were 
washed with normal Krebs and double stained with 36 μM fluorescein diacetate (FDA) 
and 7 μM propidium iodide (PI) for 20 min at 37 °C in a phosphate buffer solution. 
Stained cells were examined immediately with a standard inverse fluorescence 
microscope at 480 and 546 nm (410). PI- and FDA-positive cells were counted in three 
representative high power fields of independent cultures and cell death was determined 
by the ratio of the number of PI positive cells/PI + FDA-stained positive cells 
 
 
III.12. ROS production determination 
DCFH-DA (2',7'-dichlorfluorescein-diacetate), a cell membrane-permeable 
fluorescein analogue, was used to detect ROS production (412) in differentiated NSC-
34 motor neurons. The cells were exposed to 300 µM L-BMAA for 48 h or to chemical 
hypoxia for 45 min and then were loaded with 10 µM DCFH-DA for 30 min at 37° C 
in PBS. At the end, the cells were washed with PBS, and the reaction was stopped by 
addition of 2,6-di-tert-butyl-4-methylphenol (0.2% in ethanol) and 2 mM EDTA. 
Finally, cells were viewed with a Zeiss fluorescence microscope (Axioscope 2FS plus; 
Zeiss, Goettingen, Germany) using excitation and emission wavelengths of 488 and 
525 nm respectively. Digital images were taken with a CoolSnap camera and analysed 
with Image-Pro Plus 4.5 software. Image acquisition and processing was performed 
equally for all experimental conditions; for quantification of results, background 
fluorescence was subtracted from the data. 
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III.13.  SOD1 inactivation and measurement of SOD activity 
SOD1 was incubated with H2O2 (200 mM) in 25 mM sodium bicarbonate 
buffer (pH 7.5) for 5, 30, 60, and 120 min at room temperature. The reaction was then 
stopped by adding catalase (1000 U/mL) for 30 min at 37° C.  
Finally, SOD1 activity was measured by SOD assay kit, purchased from 
Sigma. This kit uses Dojindo’s highly water-soluble tetrazolium salt, WST-1 (2-(4-
Iodophenyl)- 3-(4-nitrophenyl)-5-(2,4-disulfophenyl)- 2H-tetrazolium, monosodium 
salt) that produces a water-soluble formazan dye upon reduction with a superoxide 
anion. The rate of the reduction with O2 are linearly related to the xanthine oxidase 
(XO) activity, and is inhibited by SOD; therefore, the IC50 (50 % inhibition activity 
of SOD) can be determined by a colorimetric method: the absorbance at 440 nm is 
proportional to the amount of superoxide anion and the SOD activity as an inhibition 
activity can be quantified by measuring the decrease in the color development at 440 
nm.    
 
 
III.14.  Statistical analysis 
Data are expressed as mean ± S.E.M. Statistical comparisons between controls 
and treated experimental groups were performed using the one-way ANOVA, 
followed by Newman Keul's test. P < 0.05 was considered statistically significant. 
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IV.1.  Characterization of NSC-34 differentiation 
Motor neuronal NSC-34 cells are a hybrid mouse-mouse cell line obtained 
from spinal cord and neuroblastoma cells that resembles motor neurons; indeed, these 
cells display a multipolar neuron-like phenotype, express choline acetyltransferase and 
neurofilament triplet proteins, and generate action potentials (243). 
Because only differentiated cells show neuritic processes, and axons, NSC-34 
cells were differentiated by the addition of 10 µM retinoic acid for 48 h and used in all 
experimental paradigms described above. 
Fig. 20A depicts NSC-34 cells before (wt NSC-34) and after differentiation 
(differentiated NSC-34) with 10 µM retinoic acid. In particular, undifferentiated cells 
showed a rounded morphology, while, after differentiation, showed long neuritic 
processes with a small rounded cell body. Moreover, in fig. 20B, immunocytochemical 
experiments showed a high expression of non-phosphorylated neurofilament protein 
SMI-32, a well know marker of motor neuron that marks cytoskeleton and axons. 
To better characterize the process of differentiation in NSC-34 motor neurons, 
the expression of some neuronal markers was analyzed in both differentiated and 
undifferentiated cells. We focused our attention on GAP-43 and nNOS, two well 
known markers of neuronal differentiation. In particular, in 1992, Cashman et al. 
demonstrated that NSC-34 cells express GAP-43 (growth associated protein 43), a 
protein found at high levels in neuronal growth cones during development and axonal 
regeneration. Thus, the expression of GAP-43 and nNOS (neuronal nitric oxide 
sinthetase) was evaluated in NSC-34 cells before and after treatment in 10 µM retinoic 
acid (fig. 20C and 20D). Both proteins were expressed in NSC-34 motor neurons, but 
their levels are significantly higher in differentiated than in undifferentiated cells (fig. 
20C – GAP-43, and 20D - nNOS).  
 
 
 
 
 
 
 
 
Results  
 
74 
 
 
 
 
 
Figure 20. Morphological and biochemical characterization of NSC-34 cells. 
A. NSC-34 motor neurons are represented before and after differentiation with 10 µM retinoic 
acid for 48 h. 
B. Immunocytochemical analysis of SMI-32 in NSC-34 motor neurons after differentiation 
with 10 µM retinoic acid for 48 h. 
C/D. Western blotting analysis of GAP-43 (C) and nNOS (D) expression levels in NSC-34 
motor neurons before (in white)  and after (in black) differentiation with 10 µM retinoic acid 
for 48 h. 
*p<0.05 vs control (wt NSC-34). 
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IV.2.  Characterization of SOD1 release from differentiated NSC-34 
motor neurons  
SOD1 is secreted in many cellular lines under basal condition and after 
depolarization mediated by high extracellular K+ concentration (322, 325). Thus, we 
verified the ability of motor neurons to release SOD1. 
Our results showed that SOD1 was secreted in NSC-34 motor neurons under 
basal condition and after depolarization. In particular, SOD1 secretion was dependent 
on extracellular K+ concentration, since it was secreted when NSC-34 cells were 
exposed to 9 and 55 mM K+; indeed, just low K+ concentration (5.5 mM) induced basal 
release of SOD1in NSC-34 motor neurons (Fig. 21A). 
Moreover, the molecular mechanism underlying SOD1 secretion is an ATP-
dependent process (322) and requires SNARE complex activation (325). To verify 
whether this secretion was Ca2+-dependent, NSC-34 motor neurons were incubated in 
a solution contained low (5.5 mM) or high (55 mM) K+ concentration in the presence 
of 50 nM ω-conotoxin, a well known inhibitor of neuronal voltage-dependent calcium 
channel, 1 µM L-nimodipine, an inhibitor of long-lasting voltage-dependent calcium 
channel, and the extracellular calcium chelator EGTA (ethylene glycol tetraacetic acid, 
1 mM). 
Our results showed that SOD1 extracellular levels strongly decreased after 
treatment with ω-conotoxin and L-nimodipine compared with SOD1 levels detectable 
after 5 min in low or high K+ alone.  Furthermore, EGTA induces a strong reduction 
of SOD1 secretion (Fig. 21B).    
Then, time-course experiments revealed that SOD1 basal secretion increased 
gradually in the first 10 min of incubation in a low K+ solution, while protein levels 
decreased after 30 min of treatment (Fig. 21C – 5.5 mM K+). Five min exposure to 
high K+ induced, instead, an increased secretion of SOD1 that, in turn, gradually 
decreased (Fig. 21C – 55 mM K+). In this respect, we observed that, while 
extracellular SOD1 levels decreased after 30 min of depolarization mediated by high 
K+ concentration, intracellular SOD1 levels notably increased (fig. 21D – 55 mM K+). 
Therefore, our results suggest that the release of SOD1 corresponded to a 
significant decrease of intracellular protein, and vicecersa.  
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Figure 21. SOD1 release in NSC-34 motor neurons. 
A. Western blotting analysis of SOD1 extracellular levels induced by 5.5 mM, 9 mM, and 55 
mM K+. 
B. Western blotting analysis of SOD1 extracellular levels induced by 55 mM K+ in presence 
of 1 mM EGTA, or 50 nM ω-conotoxin and 1 µM L-nimodipine.  
C. Time-course experiment of SOD1 release induced by 5.5 mM (in white) or 55 mM K+ (in 
black).   
D. Analysis of SOD1 intracellular levels after exposure to 5.5 mM (in white) or 55 mM K+ (in 
black). 
*p<0.05 vs control (5.5 mM K+); 
**p<0.05 vs control (5.5 mM K+); 
***p<0.05 vs control (5.5 mM K+). 
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IV.3.  Effect of SOD1 on [Ca2+]i and phosphorylation of ERK1/2 and 
Akt in differentiated NSC-34 motor neurons  
SOD1 activates the transductional pathway phospholipase C (PLC)/ protein 
kinase C (PKC), and increases intracellular Ca2+ concentration ([Ca2+]i) (403). This 
pathway activates, in turn, downstream kinases, such as ERK1/2 (extracellular signal 
regulated kinase 1/2) and Akt (327).  
In order to verify the transductional effect of SOD1 in motor neurons, we first 
analyzed the effect of SOD1 on [Ca2+]i. Thus, we observed that the administration of 
400 ng/mL SOD1 induces a strong and fast increase of intracellular Ca2+ concentration 
(Fig. 22A). This effect was observed both in the cellular body (soma) and in the 
dendrites (Fig. 22B). In particular, [Ca2+]i increase induced by SOD1 involved two 
different type of voltage-dependent calcium channels: indeed, in the presence of L-
nimodipine and ω-conotoxin, SOD1-induced [Ca2+]i increase was reduced (Fig. 22B).   
Then, we verified the ability of SOD1 to induce ERK1/2 and Akt 
phosphorylation in NSC-34 motor neurons. To this aim, cells were pre-incubated with 
400 ng/mL SOD1 for 10 and 30 min and cellular lysates were finally analyzed by 
Western blotting. 
Our results showed that, just after 10 minutes of incubation with SOD1, p-
ERK1/2 and p-Akt levels significantly increased (Fig. 22C - D).  
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Figure 22. SOD1 transductional effects in NSC-34 motor neurons. 
A. Representative trace of the effects on [Ca2+]i of 400 ng/mL SOD1 on single-cell. 
B. Quantification of the effects on [Ca2+]i of 400 ng/mL SOD1 in presence of 50 nM ω-
conotoxin or 1 µM L-nimodipine in both soma and dendrites of NSC-34 motor neurons.  
C/D. Western blotting analysis of p-ERK1/2 (C) and p-Akt (D) expression levels induced by 
400 ng/mL SOD1, pre-incubated for 10 min or 30 min.  
*p<0.05 vs control (CTR); 
**p<0.05 vs control (CTR). 
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IV.4.  Effect of SOD1 on cell death induced by L-BMAA in 
differentiated NSC-34 motor neurons 
L-BMAA is a neurotoxic non-proteic amino acid produced by cyanobacteria 
and associated with amyotrophic lateral sclerosis-Parkinson dementia complex (ALS-
PDC), a neurological disease that affects an indigenous population in Guam. Thus, 
NSC-34 motor neurons exposed to L-BMAA represent an in vitro model mimicking 
ALS, useful, in this study, to verify SOD1-mediated neuroprotection.  
Our previous researches indicated that L-BMAA has an EC50 of 300 µM and 
time course experiments revealed that the exposure to L-BMAA for 48 h reduces cell 
viability of about 50%. Thus, NSC-34 motor neurons were differentiated in 10 µM 
retinoic acid for 48 h and, then, incubated with 300 µM L-BMAA for 48 h. In order to 
verify whether SOD1 showed neuroprotective effects against L-BMAA, we performed 
a dose-response experiments. To this aim, cells were pre-incubated with 40, 400 or 
4000 ng/mL SOD1 for 10 min before exposure to the toxin (300 µM). At the end of 
treatment, cell viability was determined by MTT assay. 
Our results showed that SOD1 prevents cell death induced by L-BMAA in a 
dose-dependent manner (fig. 23A); indeed, a strong recovery of cell viability was 
observed with 400 ng/mL SOD1; thus, we used this concentration in the next 
experiments. However, also the pre-incubation with the lowest concentration of 40 
ng/mL prevented cell death. 
Moreover, we verified whether SOD1 could induce neuroprotection of  motor 
neurons through the reduction of reactive oxygen species (ROS). It is known, indeed, 
that the exposure to L-BMAA is associated with a strong increase in ROS production. 
ROS amount was detected by fluorescent microscopy, using DCFH-DA (2',7’-
dichlorfluorescein-diacetate), a cell membrane-permeable analogue of fluorescein. As 
shown in fig. 23B, SOD1 was able to reduce ROS levels induced by the neurotoxin. 
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Figure 23. SOD1 prevents cell death induced by L-BMAA. 
A. Cell viability rate determined by MTT assay on NSC-34 motor neurons pre-incubated with 
40, 400 or 4000 ng/mL SOD1 for 10 min and then exposed to 300 µM L-BMAA for 48 h. 
B. Quantification of ROS levels detected by DCF-DA-monitored microscopy induced by 300 
µM L-BMAA for 48 h in NSC-34 motor neurons pre-treated with 400 ng/mL SOD1 for 10 
min.  
*p<0.05 vs control (CTR); 
**p<0.05 vs L-BMAA; 
***p<0.05 vs L-BMAA + 40 ng/mL SOD1. 
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IV.5.  Effects exerted by recombinant wild type SOD1 and 
recombinant SOD1G93A 
Actually, some recombinant proteins with the most common mutation in the 
gene coding for SOD1 associated to ALS are commercially available. The use of these 
proteins could be useful to study ALS in vitro. One of the better characterized 
mutations in SOD1 is the aminoacidic substitution G93A. Thus, we studied the effect 
exerted by the recombinant wild type SOD1 (rSOD1 wt) and the recombinant 
SOD1G93A (rSOD1G93A) in NSC-34 motor neurons exposed to L-BMAA. 
In order to verify the ability of rSOD1 wt to prevent cell death induced by the 
neurotoxin, we performed a dose-response experiment. NSC-34 motor neurons were 
pre-incubated with 40, 400 or 4000 ng/mL rSOD1 wt, and then exposed to 300 µM L-
BMAA for 48 h. At the end of treatment, cell viability was measured by MTT assay. 
Our results showed that the rSOD1 wt, such as the extractive protein used in 
the previous described experiments, prevented cell death induced by L-BMAA in a 
dose-dependent manner (fig. 24A). 
Successively, we compared the effects mediated by rSOD1G93A with the effects 
exerted by both extractive SOD1 and rSOD1 wt. To this aim, NSC-34 motor neurons 
were pre-incubated with the same concentration (400 ng/mL/10 min) of SOD1, rSOD1 
wt and rSOD1G93A and then were exposed to L-BMAA (300 µM/48 h). 
In fig. 24B, it is shown that rSOD1 wt prevented L-BMAA-induced cell death 
in differentiated NSC-34 motor neurons, as well as extractive SOD1, while rSOD1G93A 
fails to prevent neurotoxicity. 
Collectively, our results demonstrated that the mutated protein is unable to 
prevent motor neurons death induced by L-BMAA, while the wild type protein has the 
same effects exerted by extractive SOD1, used in the previous experiments.  
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Figure 24. Effects exerted by rSOD1 wt and by rSOD1G93A on cell death induced 
by L-BMAA. 
A. Cell survival rate detected by MTT analysis in NSC-34 motor neurons exposed to 300 µM 
L-BMAA for 48 h after pre-incubation with 40, 400 or 4000 ng/mL wt rSOD1 for 10 min.  
B. Cell survival rate detected by MTT analysis in NSC-34 motor neurons exposed to 300 µM 
L-BMAA for 48 h after pre-incubation with 400 ng/mL estractive SOD1, rSOD1 wt, or 
rSOD1G93A for 10 min. 
*p<0.05 vs L-BMAA; 
**p<0.05 vs L-BMAA + 400 ng/mL SOD1. 
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IV.6.  Role of p-ERK1/2 and p-Akt  in SOD1-induced neuroprotection 
against L-BMAA  
In order to verify the involvement of p-ERK1/2 and p-Akt in the 
neuroprotection exerted by SOD1, we analyzed the effects of SOD1 after the inhibition 
of both the transductional pathways. To this aim, ERK1/2-mediated pathway was 
pharmacologically inhibited by PD98059, an inhibitor of p-ERK1/2, and genetically, 
by using a siRNA against MEK1 (siMEK1), the upstream kinase of ERK1/2. 
Furthermore, p-Akt pathway was inhibited by using LY294002, a p-Akt inhibitor, and 
the dominant negative form of Akt (Akt D-) that encodes for an inactive kinase. 
Specifically, NSC-34 motor neurons were pre-incubated for 20 min with 50 
µM PD98059 in absence or in presence of 400 ng/mL SOD1 for 10 min and then 
exposed to 300 µM L-BMAA for 48 h. Moreover, NSC-34 cells were transfected with 
10 nM siMEK1 for 48 hrs before treatment, and then incubated with 300 µM L-BMAA 
in absence or in presence of 400 ng/mL SOD1. At the end of treatments, cell viability 
was measured by MTT assay.  
Our results showed that PD98059 counteracted the neuroprotective effects 
exerted by SOD1 alone (fig. 25A). The same result was obtained in silenced cells; 
indeed, siIMEK1 prevented the neuroprotection induced by SOD1 (fig. 25A). In fig. 
25B, the efficiency of transfection has been reported: in presence of siMEK1, p-
ERK1/2 level was reduced and, of course, siMEK1 prevents the transductional effect 
of SOD1 on ERK1/2 activation.  
In another experimental condition, NSC-34 motor neurons were pre-incubated 
for 30 min with 10 µM LY294002 in absence or in presence of 400 ng/mL SOD1 for 
10 min and then exposed to 300 µM L-BMAA for 48h. Furthermore, NSC-34 cells 
were transfected with 2 µg/µL Akt D-, as previous described, and then incubated with 
300 µM L-BMAA in absence or in presence of 400 ng/mL SOD1. At the end of 
treatments, cell viability was measured by MTT assay. 
Our results showed that LY294002 and Akt D- prevented the neuroprotection 
mediated by SOD1 on L-BMAA-induced cell death (fig. 25C). In addition, in fig. 25D, 
the effect of the dominant negative form of Akt on the downstream target ERK1/2  has 
been reported; we showed that Akt D- reduced p-ERK1/2 in control conditions and 
prevented SOD1-induced ERK1/2 phosphorylation.  
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Collectively, these results indicate that SOD1-mediated neuroprotection 
requires ERK1/2 and Akt activation, suggesting that this effect is possibly linked to 
the transductional actions of SOD1 rather than its catalytic activity.  
 
 
 
Figure 25. SOD1 prevents cell death induced by L-BMAA in NSC-34 motor 
neurons through ERK1/2 and Akt phosphorylation. 
A. Cell viability rate detected by MTT assay on NSC-34 motor neurons pre-incubated with 50 
µM PD98059 for 20 min or transfected with 10 nM siMEK1 for 48 h in absence or in presence 
of SOD1 (400 ng/mL/10 min) before exposure to 300 µM/48 h L-BMAA. 
B. Western blotting analysis on p-ERK1/2 expression levels in NSC-34 cells transfected with 
20 nM siMEK1 for 48 h in absence or in presence of 400 ng/mL SOD1 for 10 min and then 
exposed to L-BMAA. 
C. Cell viability rate detected by MTT  assay on NSC-34 motor neurons pre-incubated with 
10 µM LY294002 for 20 min or transfected with 2µg/µL Akt D- for 48 h in absence or in 
presence of SOD1 (400 ng/mL/10 min) before exposure to 300 µM/48 h L-BMAA. 
D. Western blotting analysis on p-ERK1/2 expression levels in NSC-34 cells transfected with 
2 µg/µL Akt D- for 48 h in absence or in presence of 400 ng/mL SOD1 for 10 min and then 
exposed to L-BMAA. 
*p<0.05 vs control (CTR); 
**p<0.05 vs L-BMAA; 
***p<0.05 L-BMAA + SOD1. 
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IV.7.  Role of the transductional activity of SOD1 in the 
neuroprotection against L-BMAA: effect of MnTMPyP pentachloride 
and ApoSOD 
Since SOD1 prevents cell death induced by L-BMAA through p-ERK1/2 and 
p-Akt activation, we study whether this transductional activity could play a relevant 
role in these neuroprotective effects compared to the catalytic activity of the protein. 
To this aim, we compared the effects exerted by SOD1 to the effects exerted by 
MnTMPyP pentachloride, that is a SOD mimetic, and ApoSOD, the enzyme lacking 
catalytic activity. In particular, MnTMPyP pentachloride has the same catalytic 
activity of SOD1, but it shows a different molecular structure. In order to inactivate 
SOD1, we exposed the protein to 200 mM hydrogen peroxide and then we stopped the 
reaction by adding catalase (1000 U/mL). As previous described in the Method’s 
section, SOD1 activity was measured indirectly by a colorimetric assay. 
As shown in fig. 26A, our protocol reduced SOD1 activity in a time-dependent 
manner; indeed, after 2 h exposure to H2O2, SOD1 was maximally inactivated, thus 
showing lowest activity. Furthermore, we verified, by Western blotting analysis, that 
our protocol did not affect molecular structure of SOD1 protein (fig. 26B). 
In order to verify our hypothesis, we studied the eventual transductional effects 
of ApoSOD in NSC-34 motor neurons. Like SOD1, the inactivated enzyme (400 
ng/mL) induced a rapid and strong increase of [Ca2+]i both in the soma and in the 
dendrites of motor neurons (fig. 26C). This action depended on different voltage-
dependent calcium channels activity, since both ω-conotoxin and L-nimodipine 
prevented intracellular Ca2+ concentration increase induced by ApoSOD (fig. 26D). 
Moreover, ApoSOD was able to activate ERK1/2 and Akt in NSC-34 motor neurons. 
The pre-incubation with 400 ng/mL ApoSOD for 10 min, indeed, induces an increase 
of both p-ERK1/2 and p-Akt levels, such as SOD1 (fig. 26E – F).  
Finally, we analyzed the eventual neuroprotection exerted by ApoSOD and 
MnTMPyP pentachloride in NSC-34 motor neurons exposed to 300 µM L-BMAA for 
48 h. To this aim, differentiated NSC-34 cells were pre-incubated with 400 ng/mL 
SOD1, 400 ng/mL ApoSOD or 400 ng/mL MnTMPyP pentachloride for 10 min and 
then exposed to the neurotoxin. At the end of treatments, cell viability was measured 
by MTT assay.  
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Our results showed that, like SOD1, ApoSOD that lacks catalytic activity 
prevented cell death induced by L-BMAA in NSC-34 motor neurons, while 
MnTMPyP pentachloride fails to have the same effects (fig. 27A). This suggests that 
the neuroprotection mediated by SOD1 was independent on its catalytic activity. 
Moreover, we verified the involvement of p-ERK1/2 and p-Akt pathway in the 
neuroprotection exerted by ApoSOD, by inhibiting both the kinases with the p-
ERK1/2 inhibitor PD98059, and the p-Akt inhibitor LY294002.  These two drugs 
counteracted the neuroprotective effects exerted by ApoSOD (fig. 27B). 
Collectively, our results demonstrated that the neuroprotection exerted by 
SOD1 depended on its transductional effects rather than its dismutasic activity. 
 
 
 
 
Figure 26. ApoSOD transductional effects in NSC-34 motor neurons. 
A. Inactivation of SOD1 with H2O2 (200 µM /5, 30, 60, and 120 min)  
B. Western blotting analysis of inactivated SOD1 (ApoSOD).  
C. Quantification of the effect of 400 ng/mL ApoSOD on [Ca2+]i in both soma and dendrites 
of NSC-34 motor neurons.  
D. Quantification of the effect of 400 ng/mL ApoSOD on [Ca2+]i in both soma and dendrites 
of NSC-34 motor neurons in presence of 50 nM ω-conotoxin or 1 µM L-nimodipine.  
E/F. Western blotting analysis of p-ERK1/2 (E) and p-Akt (F) expression levels induced by 
400 ng/mL ApoSOD, pre-incubated for 10 min or 30 min.  
*p<0.05 vs control (CTR); 
**p<0.05 vs control (CTR). 
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Figure 27. ApoSOD prevents cell death induced by L-BMAA in NSC-34 motor 
neurons through ERK1/2 and Akt phosphorylation. 
A. Cell viability percentage determined by MTT assay on NSC-34 motor neurons pre-treated 
with 400 ng/mL SOD1, ApoSOD, and MnTMPyP pentachloride for 10 min, and then exposed 
to L-BMAA (300 µM/48 h). 
B. Cell viability percentage determined by MTT assay on NSC-34 motor neurons pre-
incubated with 50 µM PD98059 for 20 min or 10 µM LY294002 for 30 min in absence or in 
presence of 400 ng/mL ApoSOD for 10 min, and then exposed to 300 µM L-BMAA for 48 h.  
*p<0.05 vs control (CTR); 
**p<0.05 vs L-BMAA; 
***p<0.05 vs L-BMAA + ApoSOD. 
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IV.8.  Effects of SOD1 on ER stress induced by L-BMAA in NSC-34 
motor neurons  
Recent evidence shows that ER stress, usually involved in neurodegenerative 
disease, plays a key role in motor neuron degeneration typical of ALS (374). Thus, we 
studied whether the neuroprotective effects of SOD1 was due to the modulation of ER 
stress occurring after L-BMAA incubation. To this aim, ER stress markers, such as 
GRP78 (or BiP), a molecular chaperone that activates the unfolded protein response 
(UPR) in presence of misfolded proteins, CHOP (or GADD153), a transcriptional 
factor activated in presence of mitochondrial damage, and caspase-3 and caspase-12, 
two enzymes involved in apoptosis, have been studied. 
In order to verify ER stress involvement in SOD1-mediated neuroprotection, 
NSC-34 motor neurons were pre-incubated with 400 ng/mL SOD1 for 10 min and then 
exposed to 300 µM L-BMAA for 24 h or 48 h. At the end of treatments, cells were 
collected and analyzed by Western blotting in order to evaluate GRP78 expression. 
Our results showed an increase of GRP78 occurred after 24 h exposure to L-BMAA, 
and this increase was more evident after 48 h exposure. The pre-incubation with SOD1 
prevented the increase of GRP78 induced by the neurotoxin, suggesting that SOD1 
protects neurons from ER stress induced by L-BMAA (fig. 28A). 
Moreover, since our previous results indicate that the neuroprotection exerted 
by SOD1 is independent on its catalytic activity, in order to verify the ability of 
ApoSOD to prevent GRP78 increase induced by L-BMAA, NSC-34 motor neurons 
were pre-incubated with 400 ng/mL SOD1 or 400 ng/mL ApoSOD and then exposed 
to the neurotoxin (300 µM/48 h). Then, cells were collected and analyzed by Western 
blotting. In fig. 28B, it is shown that ApoSOD, like SOD1, prevented GRP78 increase 
induced by 300 µM L-BMAA after 48 h exposure.  
Collectively, our results indicate that SOD1 protected neurons from ER stress 
by ALS-mediated neurodegeneration, and this prevention seems to be independent on 
its dismutasic activity.   
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Figure 28. SOD1 and ApoSOD prevent ER stress induced by L-BMAA in NSC-
34 motor neurons. 
A. Western blotting analysis of GRP78 expression levels in NSC-34 motor neurons pre-
incubated with 400 ng/mL SOD1 for 10 min and the exposed to 300 µM L-BMAA for 48 h.    
B. Western blotting analysis of GRP78 expression levels in NSC-34 motor neurons pre-
incubated with 400 ng/mL SOD1 or 400 ng/mL ApoSOD for 10 min and then exposed to L-
BMAA (300 µM/48 h).   
*p<0.05 vs control (CTR); 
**p<0.05 vs L-BMAA. 
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IV.9.  Effects of SOD1 on cell death induced by L-BMAA in primary 
cultures of motor neurons 
Primary cultures of motor neurons were obtained from spinal cord of E12/E14 
embryo mice, as described in Material and Methods. 
These cultures were characterized by immunocytochemical analysis, 
evaluating SMI-32 (a typical motor neuron marker) expression. By confocal 
microscopy, we showed a strong expression of SMI-32, that marks the not-
phosphorylated H neurofilament, both in the soma and in the dendrites of primary cells 
(fig. 29A - B).  
In order to verify the susceptibility of primary motor neurons to L-BMAA, we 
performed a time-course experiment, by exposing cells to 300 µM L-BMAA for 24 h 
or 48 h.  
Our results showed that cell viability was reduced just after 24 h exposure to 
the neurotoxin, but a strong reduction (about 50%) was observed only after 48 h 
exposure (fig. 29C - D) 
Then, we evaluated the neuroprotective effects exerted by SOD1 and their 
molecular mechanisms. To this aim, primary motor neurons were pre-treated with 400 
ng/mL SOD1, 400 ng/mL ApoSOD, 400 ng/mL rSOD1wt, and 400 ng/mL rSOD1G93A, 
and then exposed to L-BMAA (300 µM/48 h). At the end of treatments, cell viability 
was detected by measuring the ratio between dead and living cells.  
Our results demonstrated that SOD1, rSOD wt and ApoSOD prevented in the 
same extent cell death induced by L-BMAA in primary cultures of motor neurons. On 
the contrary, the rSOD1G93A fails to have the same neuroprotective effects (fig. 29).  
Collectively, these results indicated that SOD1 prevents cell death also in 
primary motor neurons independently from its catalytic activity.  
 
 
Results  
 
91 
 
 
 
Figure 29. SOD1 prevents cell death induced by L-BMAA in primary motor 
neurons. 
A. Sequence of immunocytochemical confocal images of SMI-32 expression in primary 
cultures of motor neurons. Cells are represented at two different magnification.    
B/C. Percentage of cell viability of primary motor neurons treated with L-BMAA (300 µM) 
for 24 h or 48 h in absence or in presence of 400 ng/mL SOD1, ApoSOD, wt rSOD1, and 
rSOD1G93A for 10 min. 
*p<0.05 vs control (CTR); 
**p<0.05 vs L-BMAA; 
***p<0.05 vs L-BMAA + SOD1. 
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IV.10.  Effects of SOD1 on cell death induced by chemical hypoxia in 
NSC-34-SOD1G93A motor neurons 
To better characterize the neuroprotective effects exerted by SOD1, we tested 
the ability of SOD1 to prevent cell death induced by chemical hypoxia in stably 
transfected NSC-34 motor neurons, that express SOD1G93A after treatment with 1 
µg⁄mL doxycycline for 48 h. 
NSC-34-SOD1G93A motor neurons were pre-incubated with 400 ng/mL SOD1 
for 10 min and then exposed to chemical hypoxia for 45 min. At the end of treatment, 
cell viability was evaluated by MTT assay.  
Our results showed that the exposure to chemical hypoxia for 45 min strongly 
reduce cell viability of NSC-34-SOD1G93A motor neurons and SOD1 was able to 
prevent cell death induced by hypoxic stimulus in these stably transfected motor 
neurons (fig. 30A). 
Since SOD1 prevented cell death induced by chemical hypoxia in NSC-34-
SOD1G93A, we studied the effects exerted by two different recombinant protein, 
recombinant wt SOD1 and recombinant SOD1G93A, on NSC-34 motor neurons 
exposed to chemical hypoxia. To this aim, cells were first pre-incubated with 400 
ng/mL rSOD1 wt or with 400 ng/mL rSOD1G93A and then exposed to chemical hypoxia 
for 45 min. 
As shown in fig. 30B, rSOD1 wt prevented cell death induced by chemical 
hypoxia as well as SOD1. On the contrary, rSOD1G93A fails to induce neuroprotection 
on motor neuron against hypoxia. 
Collectively, our results showed that SOD1 exerted neuroprotective effects 
against chemical hypoxia, a Ca2+- and ROS-dependent mechanism both in wild type 
NSC-34 and NSC-34-SOD1G93A motor neurons.  
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Figure 30. SOD1 prevents cell death induced by chemical hypoxia in NSC-34-
SOD1G93A motor neurons. 
A. Cell survival rate determined by MTT analysis on stably transfected NSC-34-SOD1G93A 
motor neurons exposed to 45 min chemical hypoxia. 
B. Cells survival rate determined by MTT analysis on NSC-34 motor neurons pre-incubated 
eith 400 ng/mL SOD1, wt rSOD1, and rSOD1G93A for 10 min.    
*p<0.05 vs control (CTR); 
**p<0.05 vs Chemical Hypoxia. 
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IV.11.  Effects of transductional activity of SOD1 on chemical 
hypoxia-induced cell death in NSC-34 motor neurons 
Since SOD1 prevents cell death induced by chemical hypoxia in stably 
transfected NSC-34-SOD1G93A motor neuron, we studied the molecular mechanisms 
underlying this neuroprotection. Thus, we exposed NSC-34 motor neurons to chemical 
hypoxia, which represents an in vitro model of Ca2+- and ROS-dependent 
neurodegeneration.  
NSC-34 motor neurons were first incubated with a Krebs glucose-free solution 
containing 2 mM 2-deoxyglucose, an inhibitor of glycolisis, and 5 mg/mL 
olygomycin, an oxidative phosphorylation inhibitor, for 45, 90 and 180 min. At the 
end of treatments, cell viability was detected by MTT assay.   
Our results demonstrated that chemical hypoxia strongly reduced cell viability 
in motor neurons; indeed, just after 45 min exposure, cell viability was reduced of 
about 50% (fig. 31A).  
Successfully, we performed a dose-response experiment to verify SOD1-
mediated neuroprotection. To this aim, NSC-34 motor neurons were pre-incubated 
with 40, 400 and 4000 ng/mL SOD1 for 10 min and then exposed to 45 min chemical 
hypoxia. Cell viability, finally, was measured by MTT assay.  
In fig. 31B, it is shown that SOD1 prevented cell death in a dose-dependent 
manner. A strong recovery of cell viability was detected with 400 ng/mL SOD1, as 
revealed in motor neurons exposed to L-BMAA. 
Since chemical hypoxia is associated to a great amount of ROS, we verified 
the ability of SOD1 to prevent ROS increase in NSC-34 motor neurons exposed to 
chemical hypoxia for 45 min. 
ROS amount was detected by fluorescent microscopy, using DCFH-DA (2',7'-
dichlorfluorescein-diacetate), a cell membrane-permeable fluorescein analogue,  and 
revealed that SOD1 was able to reduce ROS levels induced by chemical hypoxia  (fig. 
31C).  
Then, we analyzed the neuroprotective effects exerted by SOD1 in motor 
neurons exposed to chemical hypoxia and reoxygenation. To this aim, NSC-34 motor 
neurons were pre-treated with SOD1 for 10 min, exposed to 45 or 90 min chemical 
hypoxia and finally to reoxygenation, by the substitution of Krebs glucose-free 
solution with a complete culture medium for 3 or 5 h.  
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As shown in fig. 31D, SOD1 prevented cell death induced also by 
reoxygenation. In particular, after 5 h of reoxygenation, we observed a strong 
reduction of cell viability (about 30% cell viability). However, SOD1 reduced cell 
death induced by hypoxia. 
Then, in order to verify the involvement of p-ERK1/2 and p-Akt in SOD1-
mediated neuroprotection in this model, we studied the effects exerted by the enzyme 
by inhibiting these two kinases.  
As previous described in NSC-34 motor neurons exposed to L-BMAA, we 
analyzed the effects of SOD1 in presence of PD98059 (a p-ERK1/2 inhibitor), siMEK1 
(that silences MEK1, the upstream kinase of ERK1/2), LY294002 (a p-Akt inhibitor), 
and Akt D- (that codes for an inactivated kinase). Thus, for the pharmacological 
treatments, NSC-34 cells were pre-treated with 10 µM PD98059 for 10 min or 50 µM 
LY294002 for 20 min in absence or in presence of 400 ng/mL SOD1. Furthermore, 
cells were transfected with 10 nM siMEK1 or 2 µg/µL Akt D-. At the end of both the 
pharmacological and the molecular treatments, cell viability was detected by MTT 
assay. 
In fig. 32A, it is shown that the pharmacological and molecular inhibition of p-
ERK1/2 prevent the neuroprotective effects exerted by SOD1. Analogously, in fig. 
32B, it is demonstrated that also the pharmacological and molecular inhibition of p-
Akt counteract SOD1-mediated neuroprotection under hypoxic conditions.  
Finally, we studied the involvement of catalytic and transductional actions of 
SOD1 in the neuroprotection in this model. 
As previous described, NSC-34 motor neurons were pre-incubated with 400 
ng/mL SOD1, 400 ng/mL ApoSODor 400 ng/mL MnTMPyP pentachloride (a SOD1 
mimetic drug) and then exposed to chemical hypoxia for 45 min. At the end of 
treatments, cell viability was detected by MTT assay. 
Our results showed that ApoSOD, lacking catalytic activity, exerted the same 
neuroprotective effects mediated by SOD1, while MnTMPyP pentachloride failed to 
have these actions (fig. 33A).  
Moreover, it seems that the neuroprotection exerted by ApoSOD required 
ERK1/2 and Akt activation. Indeed, we studied the effects of ApoSOD also in NSC-
34 motor neurons pre-treated with 10 µM PD98059 for 10 min or 50 µM LY294002 
for 20 min and then exposed to chemical hypoxia for 45 min. 
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As shown in fig. 33B, both the pharmacological inhibition of p-ERK1/2 and p-
Akt counteract the neuroprotective effects exerted by ApoSOD.  
Collectively, our results demonstrated that SOD1 prevents cell death induced 
by chemical hypoxia in a dose-dependent manner through ERK1/2 and Akt activation. 
Moreover, this neuroprotection seems to be independent on SOD1 dismutasic activity, 
because also ApoSOD, that lacked catalytic site, prevented cell death induced by 
chemical hypoxia through ERK1/2 and Akt activation.  
 
 
 
 
Figure 31. SOD1 prevents cell death induced by chemical hypoxia in NSC-34 
motor neurons. 
A. Cell viability rate of NSC-34 motor neurons exposed to chemical hypoxia for 45, 90 and 
180 min    
B. Cell viability rate of NSC-34 motor neurons exposed to 45 min chemical hypoxia after 
preincubation with SOD1 (40, 400 and 4000 ng/mL) for 10 min.  
C. Determination of ROS levels in NSC-34 motor neurons exposed to chemical hypoxia for 
45 min in absence or in presence of 400 ng/mL SOD1 for 10 min.  
D. Cell viability rate of NSC-34 motor neurons exposed to chemical hypoxia for 45 min and, 
then, to 3 h or 5 h reoxygenation in absence or in presence of 400 ng/mL SOD1 for 10 min.  
*p<0.05 vs control (Normoxia); 
**p<0.05 vs 45 min Chemical Hypoxia; 
***p<0.05 vs 40 ng/mL SOD1 
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Figure 32. SOD1 prevents cell death induced by chemical hypoxia in NSC-34 
motor neurons through ERK1/2 and Akt phosphorylation. 
A. Cell viability percentage of NSC-34 motor neurons pre-incubated with 50 µM PD98059 
for 20 min or transfected with 10 nM siMEK1 for 48 h in absence or in presence of SOD1 
(400 ng/mL/10 min) before exposure to 45 min chemical hypoxia. 
B. Cell survival rate determined by MTT  assay on NSC-34 motor neurons pre-incubated with 
10 µM LY294002 for 20 min or transfected with 2µg/µL Akt D- for 48 h in absence or in 
presence of SOD1 (400 ng/mL/10 min) before exposure to 45 min chemical hypoxia. 
*p<0.05 vs control (Normoxia); 
**p<0.05 vs Chemical Hypoxia; 
***p<0.05 vs Chemical Hypoxia + SOD1. 
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Figure 33. ApoSOD prevents cell death induced by L-BMAA in NSC-34 motor 
neurons through ERK1/2 and Akt phosphorylation. 
A. Cell survival percentage of NSC-34 motor neurons exposed to 400 ng/mL/10 min SOD1, 
ApoSOD, SOD1, and MnTMPyP pentachloride and then to 45 min chemical hypoxia.  
B. Cell survival percentage of NSC-34 motor neurons pre-incubated with 50 µM PD98059 for 
20 min or 10 µM LY294002 for 30 min in absence or in presence of ApoSOD (400 ng/mL/10 
min) before exposure to chemical hypoxia for 45 min. 
*p<0.05 vs control (Normoxia); 
**p<0.05 vs Chemical Hypoxia;  
***p<0.05 Chemical Hypoxia + SOD1. 
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IV.12.  Effects of SOD1 on ER stress induced by chemical hypoxia in 
NSC-34 motor neurons 
In order to verify in the adopted models of neurodegeneration the role of ER 
stress, a type of apoptosis documented in several neurodegenerative diseases, and to 
test the effects of SOD1 on ER stress, NSC-34 motor neurons were exposed to 45 or 
180 min chemical hypoxia after pre-incubation with 400 ng/mL SOD1. At the end of 
treatments, cells were collected and analyzed by Western blotting to evaluate the 
expression of GRP78 (a molecular chaperone), CHOP (a transcription factor), caspase-
3, and caspase-12 (two mediators of apoptosis).  
Our results showed that 45 min exposure to chemical hypoxia increased GRP78 
and CHOP protein expression levels, and this increase was more evident after 180 min 
exposure. Analogously to the results obtained in motor neurons exposed to L-BMAA, 
pre-treatment with 400 ng/mL SOD1 prevented GRP78 and CHOP increase induced 
by 45 min exposure to chemical hypoxia (fig. 34A - B).  Furthermore, we observed 
the activation of both caspase-3 and caspase-12 in motor neurons exposed to 45 or 180 
min chemical hypoxia. Interestingly, SOD1 prevented the activation of both the 
protein expression of caspases (fig. 34C -D).  
Because the neuroprotective effects exerted by SOD1 are independent on 
catalytic activity, we verified also the ability of ApoSOD to prevent the increase in 
protein expression of GRP78, CHOP, caspase-3 and 12. To this aim, NSC-34 motor 
neurons were pre-incubated with 400 ng/mL SOD1 or 400 ng/mL ApoSOD and then 
exposed to chemical hypoxia for 45 min. At the end of treatment, cells were collected 
and analyzed by Western blotting.  
As shown in fig. 35, ApoSOD protects ER from stress induced by chemical 
hypoxia. Indeed, the pre-incubation with ApoSOD prevented GRP78 (fig. 35A) and 
CHOP (fig. 35B) increase induced by hypoxia. Similarly to the effects observed for 
SOD1, ApoSOD also prevented caspase-12 (fig. 35C) induced by chemical hypoxia.  
Collectively, our results showed that SOD1 is able to protect motor neurons 
from ER stress induced by chemical hypoxia independently on its catalytic activity.   
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Figure 35. ApoSOD prevents cell death induced by L-BMAA in NSC-34 motor 
neurons through ERK1/2 and Akt phosphorylation. 
A-C. Western blotting analysis of GRP78 (A), CHOP (B), and caspase-12 (C) expression 
levels in NSC-34 motor neurons pre-incubated with 400 ng/mL SOD1 for 10 min and then 
exposed to chemical hypoxia for 45 or 90 min.    
D. Western blotting analysis of caspase-3 expression levels in NSC-34 motor neurons pre-
incubated with 400 ng/mL SOD1 for 10 min and then exposed to chemical hypoxia for 90 min.    
*p<0.05 vs control (Normoxia); 
**p<0.05 vs Chemical Hypoxia. 
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Figure 36. ApoSOD prevents cell death induced by L-BMAA in NSC-34 motor 
neurons through ERK1/2 and Akt phosphorylation. 
Western blotting analysis of GRP78 (A), CHOP (B), and caspase-12 (C) expression levels in 
NSC-34 motor neurons pre-incubated with 400 ng/mL SOD1 or 400 ng/mL ApoSOD for 10 
min and then exposed to chemical hypoxia for 45 min.    
*p<0.05 vs control (Normoxia); 
**p<0.05 vs Chemical Hypoxia. 
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CONCLUSIONS 
The first link between SOD1 and ALS was found in 1993 and led to the 
hypothesis that the disease resulted from loss of function mutations in the gene 
encoding for SOD1 (268). However, most of the mutated SOD1 preserve catalityc 
activity and thus the loss of function hypothesis was rapidly refuted.  
In addition, many evidence showed that SOD1 could be secreted in many 
cellular lines (322, 325, 326) and SOD1 secretion is impaired in ALS (366). Moreover, 
SOD1 can induce PLC/PKC pathway activation through an increase of intracellular 
calcium concentration (325), independently on its dismutasic activity.  
The idea that SOD1 could exert neuroprotective effects at neuronal levels is 
due to several evidence: 
- SOD1 administration in SOD1G93A transgenic mice could modify motor symptom of 
disease (366); 
- SOD1 is released by microglial cells and could protect against the toxicity mediated 
by 6-hydroxy-dopamine (6OHDA) (404);  
- and, at last, drugs, as the insulin-like growth factor 1 (IGF-1), partially prevent motor 
neuron loss in SOD1G93A transgenic mice through ERK1/2 activation (405). 
However, the molecular mechanisms underlie the neuroprotective effects 
exerted by SOD1 are still unknown.  
Thus, the present study highlighted the neuroprotective profile of SOD1 in two 
different models of neurodegeneration at motor neuronal level: L-BMAA-induced 
neurotoxicity, mimicking amyotrophic lateral sclerosis (ALS) in vitro, and chemical 
hypoxia, a Ca2+- and ROS-dependent cell death. 
The present data showed that SOD1 prevents cell death induced by L-BMAA 
and by chemical hypoxia in a dose-dependent way. Furthermore, our results 
demonstrated that the neuroprotection exerted by the enzyme was not correlated to its 
dismutase activity, but depended on the transductional actions exerted at the level of 
Ca2+/ERK1/2/Akt pathway. Indeed, ApoSod, the enzyme lacking catalytic activity, at 
molecular level, induced intracellular Ca2+ concentration increase, and ERK1/2 and 
Akt phosphorylation in the same extent of SOD1. Moreover, ApoSOD mimicked the 
neuroprotective effects played by SOD1 on motor neurons exposed to L-BMAA or to 
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chemical hypoxia. At last, pharmacological and biochemical inhibition of ERK1/2 and 
Akt phosphorylation prevented SOD1- and ApoSOD-induced neuroprotection.   
ALS and hypoxia are associated with endoplasmic reticulum (ER) stress, a 
pathological condition resulting to the accumulation of misfolded proteins in the ER 
lumen. Thus, both ALS and hypoxia increase the expressions of several ER stress 
markers, such as GRP78, a molecular chaperon that activates the unfolded protein 
response (UPR), CHOP, a transcriptional factor involved in UPR and able to induce 
apoptosis, and caspasis, the main apoptosis mediator.  
Molecularly, the neuroprotective effect of SOD1 and ApoSod on 
Ca2+/ERK1/2/Akt pathway determined the prevention of GRP78, CHOP, and 
caspases, suggesting that SOD1 neuroprotection passed through the prevention of ER 
stress. Interestingly,  this effect was due to Ca2+/ERK1/2/Akt pathway activation. 
Considering that SOD1 was continuously secreted from NSC-34 motor 
neurons in a Ca2+-dependent manner, and that the impairment of SOD1 secretion is 
present in ALS models (366), it is possible to speculate that the reduction of SOD1 
release from motor neurons may contribute to cell death and neuronal loss occurring 
in ALS through the reduction of Ca2+/ERK1/2/Akt pathway activation that, in turn, 
culminated in ER stress, or leaded to ER stress. 
The results of the present study contributed to identify a new biochemical 
feature of SOD1 that eventually may be considered useful to draw new therapeutical 
strategy in ALS. Furthermore, the identification of the transductional pathway 
underlying the neuroprotective effect of the enzyme may contribute to the acquisition 
of new knowledge potentially useful for the field.  
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